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Abstract 
 
Background: With an aging population and an increasing prevalence of therapy for 
atherosclerosis, it might be expected that stroke subtypes would be changing over time.  
Limited information exists on the ischemic stroke subtypes in adults in Canada.   
Methods: Patients referred to the Urgent TIA Clinic, in London, Ontario, between 
2002-2012 were included.  Secular trends were analyzed using Poisson regression 
with spline trend function.  Ischemic stroke subtype classification was validated.   
Results: 3,445 consecutive patients (mean age+SD 64.8+14.9) were included.  
Cardioembolic strokes/TIAs increased from 21% in 2002 to 56% in 2012, whereas all 
other ischemic stroke subtypes decreased (p<0.05).  Separate analysis in men and 
women showed similar results.   
Conclusions: The decrease in atherosclerotic risk factors resulted in fewer 
strokes/TIAs caused by large artery atherosclerosis.  On the contrary, cardioembolic 
strokes/TIAs have increased.  This has important implications for more intensive 
investigation and treatment to reduce the risk of recurrent embolic stroke/TIA.   
 
Keywords 
 
cerebrovascular disease (MeSH), transient ischemic attack (MeSH), cerebrovascular 
stroke, ischemic stroke subtype(s), cardioembolic stroke(s), large artery 
atherosclerosis stroke, small vessel disease stroke, lacunar infarction(s) (MeSH), 
classification (MeSH), ischemic stroke classification, secular trend(s), trends (MeSH).  
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Overview and Specific Aims of Proposed Research 
The current literature suggests that there is a lack of research on the epidemiology of 
ischemic stroke subtypes in the Canadian adult population.  The specific aims of the 
present study are to assess the secular trends of ischemic stroke subtypes and describe 
their risk factors using a validated classification system. We performed a retrospective 
case series study of patients diagnosed with minor stroke or transient ischemic attack 
(TIA) between the years 2002 and 2012 (inclusive).  Our results provide evidence that 
may help prevent recurrent strokes or TIAs in this high-risk population.  In this 
chapter, we will review the epidemiology of cerebrovascular disease and ischemic 
stroke subtypes, as well as their risk factors, followed by an overview of the 
development of previous classification systems of ischemic stroke subtypes.  
 
1.2 Definition of Cerebrovascular Disease 
Cerebrovascular disease is a heterogeneous group of medical conditions caused by 
disorders of the blood circulation in the brain and nervous system.  These disorders 
result in either prolonged or transient loss of blood supply to the affected areas of the 
brain, leading to necrosis or ischemia of brain tissue, respectively.  In the case of 
prolonged ischemia, permanent necrosis of brain tissue is commonly referred to as an 
infarction or ischemic stroke, whereas transient ischemia is referred to as a TIA.  
According to the World Health Organization (WHO), stroke is defined as a syndrome 
of “rapidly developing clinical signs of focal (at times global) disturbance of cerebral 
function, lasting more than 24 hours or leading to death with no apparent cause other 
than that of vascular origin”.1  TIA was initially defined as a cerebrovascular event 
with symptoms lasting less than 24 hours,
2
 whereas the new definition introduced in 
2009 by the American Heart Association and American Stroke Association, refers to 
an “ischemic event in the brain, spinal cord or retina that leads to neurological 
symptoms without any acute and permanent tissue necrosis”.3  
 2 
Stroke and TIA have many subtypes.  They can be broadly divided into two 
categories; hemorrhagic and ischemic.  Hemorrhagic stroke can be caused by a 
rupture of the arteries in the brain (resulting in a hemorrhage into brain tissue – for 
example, Intra-Cerebral hemorrhage or ICH), or bleeding between the membranes 
surrounding the brain (resulting in Sub-Arachnoid Hemorrhage or SAH).
4
  Ischemic 
stroke or TIA can be caused by a broad group of medical conditions, such as 
atherosclerosis, cardiac disease, small vessel disease or other unusual causes (for 
example, dissection, vasculitis).
4
  Thus hemorrhagic stroke is the clinical outcome of 
excess blood in the brain tissue or the surrounding areas, whereas ischemic stroke or 
TIA is the result of limited blood circulation and nutritional supply to particular areas 
in the brain.  Hemorrhagic strokes account for approximately 13% of all incidents of 
cerebrovascular events and ischemic strokes account for 87% of such events.
5
  The 
focus of this thesis will be limited to the study of ischemic strokes or TIAs, as they 
represent a large majority of the cerebrovascular disease burden.  For the purpose of 
this paper, ischemic stroke or TIA will be referred to as stroke/TIA.   
 
1.3 Epidemiology of Cerebrovascular Disease 
Cerebrovascular disease is a major health concern worldwide.  In the year 2005, 16 
million new strokes were reported in patients who had no previous history of stroke, 
with 5.7 million patients suffering a fatal stroke.
6
  The WHO predicts that patients 
with first-ever stroke are expected to increase to 23 million, with 7.8 million expected 
to die from a stroke by the year 2030 worldwide.
7
   
There is large regional variation in the incidence of stroke.  The WHO MONICA 
cross-sectional study indicated that Finland, Lithuania and Russia have the highest 
incidence of stroke among 18 countries studied.
8
  In this study, differences in risk 
factors were responsible for 42% of the variation in stroke rates in women.
8
  Therefore, 
continual study of risk factors and subtypes of stroke/TIA is necessary over the course 
of many years, and ideally should be limited to a well-defined catchment area.  
 
 3 
In previous years, stroke was the third most common cause of death and has only very 
recently fallen to fourth place overall.
9
  Currently, in Canada, a stroke occurs every 10 
minutes, and at present there are approximately 315,000 stroke survivors who live 
with some degree of permanent disability.
10, 11
  Between the years 1953 and 1978, 
there was a decrease by 51% in deaths due to stroke, which has been attributed to 
better medical control of blood pressure.
12
  A similar decrease was recorded in 
London, Ontario, between the years 1977 and 1984, when hospital admissions due to 
stroke decreased from 500 to 250 per year.
13
  The decline was almost entirely due to 
reduction of ICH and lacunar infarction, with no change in strokes due to large artery 
atherosclerosis disease.
13
  A survey conducted in Middlesex County in Ontario 
between the years 1981 and 1982 showed that 92% of hypertensive individuals were 
treated for hypertension and 72% had well-controlled blood pressure.
14
  
More recently, between the years 1994 and 2001, there was a 27.6% decline in 
hospitalization due to stroke of all causes and a 28.2% decline in stroke-related 
mortality throughout the country.
15
  In 2004, in Canada, 53,629 hospital admissions 
and 14,591 deaths occurred due to acute stroke.
15
  However, an increase in obesity 
was observed in the Canadian population from 10% in 1970 to 24.1% in 2007-2009; 
as well, an increase in obesity-attributed strokes from 5% in the year 1970 to 11% in 
the year 2004 has been documented in other countries.
16, 17
   
Currently, 20% of all cardiovascular deaths are caused by stroke.
18
  Moreover, Ontario 
currently ranks third among the Provinces in the prevalence of cardiovascular risk 
factors; residents in Ontario ranked second in smoke-free habits and sixth in physical 
activity.
19
  Ontario residents ranked fourth in terms of healthy body weight, as well as 
fruit and vegetable consumption.
19
  Together these results suggest that there is an 
unfavorable alteration in risk factors such as body weight and physical activity.  
Consequently, the results of our study can be generalized only to Ontario residents and 
cannot be extrapolated to all Canadians.  Secular trends in stroke/TIA subtypes and 
risk factors should ideally be studied together, to identify areas that require more 
intensive prevention strategies.  Below we provide definitions and discuss the 
epidemiology of stroke/TIA subtypes.   
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1.4 Definition of Stroke/TIA Subtypes 
In this section, we provide a brief overview of stroke/TIA subtypes.  Based on the 
identified etiological mechanism that contributed to any given cerebrovascular event, 
stroke/TIA is divided into five subtypes: large artery atherosclerosis, cardioembolic 
origin, small vessel disease, stroke/TIA of other determined (unusual or rare) cause, 
and stroke/TIA of undetermined etiology.
20
  
Large artery atherosclerosis is defined as the formation of atherosclerotic plaques in 
the large diameter vessels that supply the brain with blood.  These plaques reduce the 
delivery of blood to the brain.  The decreased blood flow results in ischemia or 
necrosis due to decreased oxygenation and nutritional supply to the brain tissue.  The 
mechanism operates when platelet aggregates form on roughened plaques and parts of 
the aggregates or the plaques themselves detach from the arteries, and enter the distal 
blood circulation.  These emboli can then block the blood circulation in the smaller 
diameter vessels.  Therefore, large artery atherosclerosis stroke/TIA is the outcome of 
the sequence of plaque formation, plaque rupture, thrombus formation on ruptured 
plaque, and embolization of thrombus or plaque fragments into the arterial vascular 
system supplying oxygenated blood to brain tissue.  
In cardioembolic stroke/TIA, a blood clot originates centrally in the heart or aorta 
and circulates to the brain tissue.  In particular, the oxygenated blood from the heart 
carries these embolic particles that can potentially cause ischemia or necrosis in any 
type of tissue if they block arteries.  Moreover, cardioembolic stroke/TIA is typically 
caused by cardiac conditions that involve the cardiac rhythm, cardiac valves or the 
ability of the heart muscle to contract and send blood to the brain and the rest of the 
body (such as post-myocardial infarction, chronic heart failure, or atrial fibrillation).   
The third type of stroke/TIA is characterized as small vessel disease (also known as 
lacunar infarction) where a small area of brain tissue (less than 15mm in diameter on 
brain imaging) is necrotic or ischemic.
21
  Distinct stroke syndromes arise from the 
formation of small vessel disease stroke/TIA at particular parts of the brain supplied 
by smaller-sized arteries.  The five well validated clinical syndromes of small vessel 
disease include pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, 
sensorimotor stroke and dysarthria-clumsy hand syndrome.
22
   
 5 
In stroke/TIA classified as “other” determined etiology, unusual or rare medical 
conditions are present, such as inflammation of the arteries (e.g. vasculitis), dissection 
of the arterial wall, disorders of blood cells, or genetic diseases.   
Finally, there are strokes/TIAs for which the cause of the presenting event cannot be 
identified by investigations performed at the time of the event.  These events are 
categorized as strokes/TIAs of “undetermined” or “unknown” etiology.   
 
1.5 Epidemiology of Stroke/TIA Subtypes  
In this section, we provide a brief overview of the epidemiology of stroke/TIA 
subtypes worldwide.  The results of a literature review performed for this thesis show 
considerable variation in the epidemiology of stroke/TIA subtypes in different 
geographic areas (Appendix A).   
In Europe and the United States of America (U.S.A.), there is inconsistency between 
epidemiological studies assessing the distribution of stroke/TIA subtypes.  The largest 
study conducted to date, including 5,298 patients, was based in Switzerland during the 
years 1979-1987 and 1996-2003 and showed a decrease in large artery atherosclerosis 
from 45% to 26%, and an simultaneous increase in cardioembolic strokes from 18% to 
28%.
23
  Similar trends were evident in more recent reports from Spain.
24
  Yet studies 
in other European nations observe that the most common stroke/TIA subtypes are due 
to large artery atherosclerosis
25-34
 or small vessel disease.
35-41
  One of the largest 
studies in the U.S.A., in the years 1982-1985, showed that 73% of patients with 
ischemic stroke had large artery atherosclerosis,
42
 whereas a more recent population-
based study showed that 20% had cardioembolic stroke, which was the most common 
subtype.
43
  Other studies showed the predominance of either large artery 
atherosclerosis
44
 or small vessel disease strokes 
45-48
 in different areas of the country 
with different racial population composition, access to health and management of 
stroke risk factors.  
In contrast to studies performed in Europe and the U.S.A., early and more recent 
studies from South America and Asia show a consistently higher prevalence of small 
vessel disease.  Rojas et al
49
 from Argentina and Lee et al
50
 from Taiwan found that 
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small vessel disease was prominent in their populations even after stratifying by age.  
Small vessel disease has consistently remained the most prevalent stroke/TIA subtype 
over many years in Asia, even if there is an overall decreasing trend in this subtype.
51
  
It would be expected that given the trend in decreasing small vessel disease, there will 
be a proportional increase in other stroke/TIA subtypes in this population.  However, 
this has not yet been observed.
51
  Genetic factors might be responsible for the high 
prevalence of small vessel disease in Asians,
52
 whereas lifestyle and risk factors may 
account for this in South Americans.
53
  
It is impressive that differences in the classification systems account for significant 
variations in stroke/TIA subtypes within the same country or population.  In Patra, 
Greece, Polychronopoulos et al
33
 showed that 37% of patients had large artery 
atherosclerosis as the most prominent subtype, whereas Vemmos et al
54
 in Athens, 
Greece, observed a predominance of cardioembolic strokes/TIAs in 31% of patients 
for the same period of time.  Similarly, Sempere et al
41
 from Segovia in Spain 
demonstrated that 31% of patients had small vessel disease as the most prevalent 
subtype, whereas Arboix et al
24
 showed that in Barcelona, Spain, 28% of patients had 
predominantly cardioembolic stroke/TIA.  Regional differences in the distribution of 
risk factors and misclassification bias may account for the aforementioned differences.  
Consequently, it is not possible to provide summary statistics of previous literature for 
all stroke/TIA subtypes over the past decades.   
There is a burgeoning literature showing that the prevalence and effectiveness of 
management of stroke risk factors play the most significant role in the distribution of 
stroke/TIA subtypes, even among different ethnoracial groups.  Koch et al
47
 and 
Uchino et al
55
 from the U.S.A., Saposnik et al
53
 from Argentina, Sharma et al
56
 from 
Singapore and Feigin et al
57
 from New Zealand demonstrate that patients from 
different ethnic groups in a defined geographical area have similar distributions of 
stroke/TIA subtypes.  The latter might be related to the shared prevalence of risk 
factors for stroke/TIA within an area, rather than the genetic predisposition to specific 
subtypes of stroke/TIA related to ethnicity.   
A recent study from Norway by Ihle-Hansen et al
58
 showed that small vessel disease 
was more frequent than expected.  In this study, 31% of patients had small vessel 
disease, and equally 31% of patients had cardioembolic strokes.  Comparable results 
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were shown earlier from the Northern Manhattan Study, U.S.A., where White et al
59
 
showed that between the years 1993 and 1997, equal numbers of patients had 
cardioembolic stroke and small vessel disease, each accounting for 20%.  This finding 
addresses the importance of continual study of risk factors and stroke/TIA subtypes to 
develop more intensive prevention strategies as well as considerations related to the 
management of acute stroke/TIA.   
Currently, there are no studies in a Canadian population in a geographically defined 
area assessing stroke/TIA subtypes and their risk factors in all adults, which is what 
this present work hopes to address.  A previous study showed that cardioembolic 
strokes are marginally more prominent in young patients only, but there has been no 
report on adults older than 45 years old.
60
  Moreover, in 2009, 90% of Canadians had 
at least one risk factor for cerebrovascular or cardiovascular disease.
10
  Therefore, a 
reference study is needed as a starting point, and more studies are required to 
demonstrate the distribution of stroke/TIA subtypes and their risk factors, for the 
development of primary and secondary prevention strategies.  Below, we will discuss 
how risk factors for stroke are associated with stroke/TIA subtypes.   
 
1.6 Ischemic Stroke Subtypes and Risk Factors 
According to Fletcher, risk factors are conditions that may lead to a specific disease in 
exposed individuals more frequently than in those people who are not exposed.
61
  
Stroke risk factors are divided into non-modifiable (age, sex, genetic predisposition) 
and modifiable (e.g., hypertension, diabetes mellitus, obesity).
62
  A meta-analysis by 
Hackam and Spence showed that the use of aspirin, statins, medications for 
hypertension, as well as smoking cessation, exercise and Mediterranean diet could 
reduce the risk of recurrent stroke by more than 80%, and the number of patients who 
would be needed to treat to prevent one stroke in ten years with more intensive 
medical treatment was only three.
63
  Therefore, early identification and treatment of 
risk factors for stroke can dramatically reduce the burden of cerebrovascular disease.   
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1.6.1 Non-Modifiable Risk Factors for Stroke/TIA 
 
Age, Sex and Stroke/TIA 
Statistics Canada reports that life expectancy is increasing.
64
  Indeed, life expectancy 
in the years 1970-1972 in Canada was 69 years for men and 76 years for women, 
whereas in the years 2007-2009, specifically in Ontario, life expectancy increased to 
79 years for men and 84 years for women.
64
  With this change, it is expected that in 
the future, there will be an increase in elderly individuals surviving in the general 
population
65
, and this age related phenomenon is expected to contribute to an overall 
increased stroke prevalence.
66
  
The risk of each stroke/TIA subtype differs across age groups.  Young patients 
(age<50) are more likely to have minor cardiac sources of embolism (e.g., patent 
foramen ovale, atrial septal aneurysm, etc.),
67
 whereas the elderly have a higher 
likelihood of developing atrial fibrillation (AF) causing cardioembolic strokes.
68
  
Middle-aged individuals are more likely to have large artery atherosclerosis and small 
vessel disease and a higher prevalence of hypertension, diabetes mellitus, obesity, 
smoking or hyperlipidemia.
67, 68
  Moreover, individuals who have a high prevalence of 
atherosclerotic risk factors may die early; therefore, older survivors have a higher risk 
of developing AF and, consequently, cardioembolic strokes/TIAs.
68
  
Overall, men tend to have more strokes than women.
69
  This difference diminishes in 
older age groups, with older women having a higher incidence of clinically severe 
first-ever stroke/TIA as compared to men.
69
  On the one hand, women have a longer 
life expectancy
65
 and older women are more prone to AF, which increases with age 
and can lead to cardioembolic stroke/TIA.
68, 70
  Also, young women have a greater 
incidence of low risk cardiac sources of embolism as compared to young men.
67
  On 
the other hand, men have a higher prevalence of atherosclerotic risk factors earlier in 
life and tend to have a greater degree of large artery atherosclerosis, small vessel 
disease, or undetermined etiology of their stroke/TIA at a younger age than women.
68, 
70
  In summary, very young (age<50) and very old (age>85) women are expected to 
experience a first-ever cardioembolic stroke/TIA, in contrast to men, who will 
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experience a first large artery atherosclerosis or small vessel disease stroke/TIA in 
middle age.
67, 68
   
 
Ethnicity and Stroke/TIA 
Many studies show different results in stroke/TIA subtypes among different ethnic 
groups.  It has consistently been shown that Asians and South Americans have a 
higher prevalence of small vessel disease, whereas Caucasians are more prone to 
cardioembolic and large artery atherosclerosis stroke/TIA.   
Differences between ethnic groups within the same country have been reported.  
Black patients in the Johannesburg Registry, South Africa, were prone to small vessel 
disease more often than white patients, but with a higher rate of undetermined causes 
of stroke/TIA.
71
  In this registry, black patients were approximately ten years younger, 
were less likely to smoke and have AF or high cholesterol, and were equally 
hypertensive and diabetic compared to whites.
71
  Similarly, African Americans in the 
U.S.A. also tend to be younger at the time of their first stroke/TIA.
72
  They are more 
hypertensive and diabetic compared to whites in the U.S.A., denoting the important 
effect of Western diet and lifestyle in the development of hypertension and diabetes in 
genetically susceptible races (people of African descent are more likely to carry a 
mutation that increases sodium reabsorption from their kidneys; consequently, they 
are prone to hypertension with an increase in dietary sodium, a condition known as 
Liddle’s syndrome).72  Similar results were shown in the South London Ethnicity and 
Stroke study, United Kingdom, where the increased prevalence of obesity, diabetes 
and hypertension led to a significant increase in small vessel disease, despite the 
decrease of smoking, AF and myocardial infarction, which explained the decrease in 
large artery atherosclerosis and cardioembolic strokes/TIAs in black patients (mainly 
from the Caribbean) compared to whites.
73
   
Even if these regional differences in risk factors between ethnic groups seem to affect 
stroke/TIA subtypes, there is evidence demonstrating the complexity of developing 
specific stroke/TIA subtypes.  Previous studies have shown that populations in a 
geographically defined area share a common distribution of stroke/TIA subtypes 
among different ethnic groups.
47, 53, 56, 57
  Equal access to health care and appropriate 
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primary prevention strategies towards controlling risk factors related to specific race 
characteristics, can reduce the risk of particular stroke/TIA subtypes in more 
susceptible populations (for example, appropriate treatment of hypertension in 
Africans), eliminating the effect of race on the overall risk of stroke and in particular 
stroke/TIA subtypes.
74
   
 
1.6.2 Modifiable Risk Factors for Stroke/TIA 
 
Smoking and Stroke/TIA 
Smoking is an unhealthy behavior that promotes cerebrovascular disease (among other 
maladies).  One in three men and one in four women die prematurely because of 
various diseases caused by cigarette smoking.
75
  Since the beginning of the 
Framingham study, exposure to smoke has been shown to increase the risk of stroke.
76
  
A more recent meta-analysis suggests that there is a probable causal relationship 
between smoking and stroke even after adjusting for other risk factors,
77
 and other 
evidence shows that smoking triples the risk of a fatal stroke.
78
  In Canada, there are 
11,000 deaths per year related to heart disease and stroke attributable to smoking and 
it is estimated that one million Canadians will die in the next two decades because of 
tobacco use.
79
  There is a dose-response relationship between cigarettes smoked and 
the risk of large artery atherosclerosis and small vessel disease, especially in men.
80
   
 
Nutrition, Body Mass Index and Stroke/TIA 
A balanced diet is an important component in stroke prevention.  Based on data from 
Statistics Canada, fat comprises more than 35% of the daily nutritional intake of more 
than 25% of middle-aged Canadians.
81
  The most appropriate diet to maintain a 
healthy lifestyle and reduce the overall risk of stroke is probably the Mediterranean 
Diet from Crete, Greece.  Keys et al. in 1986 compared 15 groups from different 
countries and showed that residents from Crete had lower death rates compared to 
residents from different countries.
82
  Risk factor distribution was equal between all 
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study groups except for diet, where inhabitants of Crete had consumed a low protein 
diet.
82
  Analysis of this diet has shown that it is suitable for promotion of a healthy 
lifestyle because it is rich in olive oil, legumes, fruits and vegetables and low in meat 
and dairy products.
83
  This diet helps to reduce coronary heart disease, known to be 
related to atherosclerosis.
83
  
Increased body weight (obesity) has been related to carotid atherosclerosis, which 
significantly increases the risk of stroke/TIA.
84
  A meta-analysis of more than 2 
million participants showed that overweight people had a 22% relative increased risk 
of stroke and obese people had a 64% relative increased risk of stroke, even after 
adjusting for all other risk factors.
85
  Evidence shows that there is a linear association 
between increasing body mass index (BMI) and increasing risk of stroke in women.
86
  
Moreover, increased BMI has been related to increased risk of all large artery 
atherosclerosis, small vessel disease and cardioembolic stroke/TIA subtypes, with a 
linear relationship between increasing BMI and increasing blood pressure and non-
HDL cholesterol levels.
87
   
 
Blood Pressure and Stroke/TIA 
Increased blood pressure or uncontrolled hypertension is the most important 
modifiable risk factor for stroke.  In Canada, a 2009 survey showed that 22% of the 
population had hypertension, among which 65% had adequate control of their blood 
pressure.
88
  This was a significant improvement in the control of blood pressure since 
the year 1992, when another survey showed that 20% of the population was known to 
have hypertension and only 14% achieved a desirable level of blood pressure 
control.
88
  The increase in the control of blood pressure was attributed to the increase 
in awareness of the importance of measuring blood pressure and identifying 
hypertension by 25.6% and to the increase in appropriate treatment by 44.4% between 
the years 1992 and 2009, when the aforementioned studies were conducted.
88
  This 
was also demonstrated by the significantly increasing trend in visits to primary health 
care practitioners for control of increased blood pressure.
89
  
Nonetheless, the almost half of individuals inadequately treated for hypertension have 
a higher risk of stroke/TIA.
90
  A number of randomized controlled trials have shown 
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that this risk can be reduced by lowering blood pressure.  The Perindopril Protection 
Against Recurrent Stroke (PROGRESS) Trial showed that reduction of either systolic 
or diastolic blood pressure or both, can reduce the risk of stroke.
91
  Arboix et al 
showed that increased blood pressure is a significant risk factor for both small vessel 
disease and large artery atherosclerosis, which is consistent with other observational 
studies.
92
   
 
Diabetes Mellitus and Stroke/TIA 
Diabetes Mellitus (DM) is a significant risk factor for stroke.  According to Statistics 
Canada, approximately 2 million residents in the year 2005 lived with diabetes, and by 
the year 2016, diabetics are expected to increase to 2.4 million.
93
  A meta-analysis of 
698,782 stroke patients showed that individuals with diabetes had 2.27 times higher 
risk of ischemic stroke.
94
  Also, based on the 2011 report of the American Heart 
Association and American Stroke Association, observational studies show that 
diabetes increases the risk of stroke from 1.8 to 6 times.
95
   
There is an association between diabetes and specific stroke/TIA subtypes.  Increased 
blood glucose had been mostly related to small vessel disease strokes,
96-99
 but there 
are also studies showing a significant role of diabetes in large artery atherosclerosis 
ischemic strokes.
96, 100, 101
  Patients with abnormal Oral Glucose Tolerance Test 
(OGTT) and yet no diagnosis of diabetes had increased risk of large artery 
atherosclerosis, which indicates that high glucose levels might be involved at the 
initial stages of the atherosclerotic process.
102
  Moreover, patients with diabetes are 
more likely to have atherosclerosis of the intracranial large arteries as compared to the 
carotid arteries of the neck, and are more likely to have detection of atheroembolic 
microemboli particles in ultrasound monitoring of the arteries inside the brain, a 
condition that increases their risk of large artery atherosclerosis stroke/TIA.
103
  Some 
studies demonstrate that uncontrolled diabetes is related to increased risk of AF and, 
consequently, increased risk for cardioembolic stroke/TIA.
100, 104
  Overall, there is 
evidence showing that diabetes increases the risk of small vessel disease, large artery 
atherosclerosis and cardioembolic stroke/TIA subtypes.
104, 105
   
 
 13 
Dyslipidemia and Stroke/TIA 
High levels of blood lipids involve in the pathophysiology of cerebrovascular disease.  
Increased Low-Density-Lipoprotein (LDL) cholesterol and triglycerides are 
independent risk factors for stroke,
106
 whereas high levels of High-Density 
Lipoprotein (HDL) cholesterol can significantly reduce this risk.
107
  Currently in 
Canada, almost 40% of residents have increased cholesterol, which translates to 
approximately one million Canadians with cholesterol levels above the normal 
range.
108
   
Increased levels of LDL cholesterol are related to large artery atherosclerosis and small 
vessel disease after adjusting for age and sex, and the relation between LDL and stroke is 
significant only for large artery atherosclerosis after further adjusting for HDL cholesterol, 
triglycerides, systolic blood pressure, fasting blood glucose, BMI, current alcohol 
consumption and smoking, regular exercise and electrocardiogram abnormalities.109  The 
Stroke Prevention by Aggressive Reduction in Cholesterol levels (SPARCL) randomized 
clinical trial showed that lowering LDL cholesterol could prevent strokes, and that this 
relationship was linear.110  Additional results from this clinical trial showed that reducing 
LDL cholesterol was associated with a 33% decrease in all types of stroke in patients with 
carotid stenosis due to carotid atherosclerosis.111   
 
Cardiac Disease and Stroke/TIA 
The most common cardiac disease associated with increased risk of stroke is AF.  
Results from the Framingham Study showed that among 5,070 people followed for 34 
years, those who developed AF had almost a 20% higher risk of stroke.
112
  This risk 
was age-dependent; the attributable risk of stroke from AF increased from was 1.5% 
to 23.5% at age 50-59 and >80 years, respectively.
112
  Similar results were 
demonstrated almost 10 years later in Scotland, where Stewart et al observed middle-
aged individuals over a 20 year period of time and found similar results.
113
  Krahn et 
al showed that in Manitoba, Canada, 7.5% of air-crew male participants developed AF 
over the 44-year study period and this risk again increased in relation to increasing 
age.
114
 Elderly women with a first stroke had a higher prevalence of AF.
115
  Based on 
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estimates from the Heart and Stroke Foundation, approximately 350,000 Canadians 
have AF, which causes approximately 15% of all strokes.
116
   
Myocardial Infarction (MI) preceding a cerebrovascular event is another significant 
cardiac condition related to stroke.  Patients with MI have a higher risk of stroke in the 
month following their heart attack and are more likely to have a fatal stroke; this risk 
is reduced and is not significantly different from controls after the first 12 months 
following the heart attack.
117
  Moreover, Wienbergen et al found that 1.2% of 21,330 
patients had a stroke following a MI.  In this population, age, previous stroke and AF 
were significant factors that increased the risk of stroke after a MI.
118
  This was also 
shown in a more recent study in Massachusetts, where 1.4% of patients with MI 
experienced a stroke and had an increased prevalence of AF.
119
   
Additional cardiac conditions are related to increased risk of stroke.  Paradoxical 
embolism is a well-defined cause of stroke.
120
  This condition refers to the presence of 
an arterial and venous blood mixture through a hole in the heart at the level of right 
and left cardiac atria that represents a remnant from the embryonic period of life 
called a Patent Foramen Ovale (PFO).
120, 121
  Similar mixture of the arterial and 
venous blood circulation can be found in the lungs allowing the transfer of emboli 
from venous to arterial circulation.
122
  This condition results in the access of these 
emboli to the brain and all other organs, instead of being cleared by the lungs, which 
normally act as a major filter for emboli found in the venous circulation.
120
  There is 
an increased risk of stroke in patients younger than 55 years having one of these two 
communication pathways, and even greater risk in patients who have both conditions 
present.
123
  Almost 40% of patients with cryptogenic or unknown stroke have a PFO 
versus 10% of normal controls.
121
  Moreover, a larger diameter of PFO with an 
increased level of communication between the two parts of the heart relates to an 
increased risk of additional strokes.
124
  
 
Collectively, the aforementioned risk factors increase the risk of stroke and particular 
stroke/TIA subtypes.  The knowledge of the distribution of these medical conditions 
will help primary care physicians to intensively treat these risk factors and achieve 
more adequate primary prevention of stroke.  Moreover, in the aftermath of a stroke, 
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awareness of the most prevalent stroke/TIA subtypes and risk factors will aid in 
implementation of tailored treatment options to decrease the overall burden of 
cerebrovascular disease.  Therefore, our study results will provide information for 
both primary and secondary prevention strategies, given that the collection of clinical 
measurements at the time when patients experience their first stroke/TIA represent the 
most prominent risk factors that remain untreated. 
 
1.7 Classification of Stroke/TIA Subtypes 
In this section, we will discuss in brief the development of past classification systems 
of stroke/TIA and a newly developed system for classifying the etiology of stroke/TIA.  
Our goal is to provide the background evidence demonstrating the need to modify 
previous classification systems with the use of more advanced diagnostic tests and 
with an improved understanding of mechanisms of the underlying diseases.  Taken 
together, we will furnish an informative classification system, to study the distribution 
of stroke/TIA subtypes, and inform policy makers to intensify prevention strategies 
towards the most predominant ischemic stroke subtypes and related medical 
conditions.   
The first systematic classification system came from the Harvard Cooperative Stroke 
Registry, published in the year 1978 from a single center in Massachusetts, U.S.A.
125
  
According to this classification in its seminal series, 34% of patients had large artery 
atherosclerosis, 19% of patients had small vessel disease and 31% of patients had 
cardioembolic or unknown cause of stroke/TIA.
125
  The diagnosis of stroke/TIA 
subtypes was mainly based on clinical signs and symptoms, and large vessel 
atherosclerosis was a diagnosis of exclusion.
125
  Patients with cardiac and 
atherosclerotic source of embolism, and patients with unknown cause of stroke/TIA 
were classified under a single category, named “embolic”.125  At that time, there were 
limited diagnostic tests offered for imaging of the brain and the cardiac sources of 
embolism.
126
  Only 3% of patients had Computed Tomography (CT) and the vast 
majority had angiography.
126
  Ultrasound of the heart (echocardiography) was not 
offered for diagnostic purposes.
126
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With the improvement of diagnostic investigations, the Stroke Data Bank (SDB) 
classification system was developed in the following decade, including a multi-ethnic 
population from different centers.
46
  At that time, 97% of patients had CT and 
echocardiogram was regularly used,
126
 but Magnetic Resonance Imaging (MRI) had 
just started to develop and was not provided regularly in clinical practice.
46
  For the 
first time, it was noted that the presence of infarcts in different arterial territories and 
hemorrhagic transformation of the infarct favor the diagnosis of cardioembolic 
stroke.
46
  Also, it was recognized for the first time that emboli could arise from 
atherosclerotic plaques and lead to embolic stroke from large artery atherosclerosis 
disease.
46
  Based on SDB, 9% of patients had large artery atherosclerosis, 27% had 
small vessel disease, 19% had cardioembolic, and 45% had unknown cause of 
stroke.
46
  The impressive differences between SDB and Harvard Cooperative Stroke 
Registry arise from the more frequent use of CT that classified more cases as small 
vessel disease that were previously classified as large artery atherosclerosis due to 
differences in definitions of large artery atherosclerosis (stenosis≥90% in angiography 
in SDB versus total occlusion or diagnosis of exclusion in Harvard Cooperative Stroke 
Registry).  Nonetheless, with the absence of MRI, strokes arising from atherosclerotic 
basilar artery stenosis could not be differentiated from small vessel disease, resulting 
in a decrease in large artery atherosclerosis.
46
  Also, cases that were previously 
classified as large artery atherosclerosis as a diagnosis of exclusion are now classified 
as unknown causes of stroke, inflating the number of cases where no cause of stroke 
could be identified.
46
   
The use of MRI and the better understanding of mechanisms of cerebrovascular events 
led to the development in the year 1993 of the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) classification system.
127
  The initial goal of this classification 
was to better categorize stroke/TIA subtypes in patients participating in clinical trials 
assessing new therapies, and has been thereafter used in most epidemiological 
studies.
127
  According to TOAST, patients who had more than one reason to have a 
stroke/TIA were classified as “undetermined or unknown etiology of stroke”, and 
patients who had the clinical diagnosis of large artery atherosclerosis but stenosis 
≤50% were also classified as undetermined cause of stroke.127  This first problem was 
resolved in the year 2005 when the Causative Classification System (CCS) of acute 
ischemic stroke was published, and patients with multiple causes for stroke were 
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classified according to the most probable cause of the presenting stroke event.
128
  The 
second problem of TOAST led us to develop the SubtyPes of ischAemic stRoKe 
cLassification systEm (SPARKLE), which uses an ultrasound-based measurement of 
carotid atherosclerosis (total plaque area, TPA)
129
 for more accurate classification of 
large artery atherosclerosis and is used for the classification of ischemic stroke 
subtypes in the present study. 
In previous classification systems, before SPARKLE, peak velocity of the blood flow 
with a stenosis ≥50% has been used as a measure of carotid stenosis and large artery 
atherosclerosis disease.  However, high measurements of blood flow velocity can be 
found in normal vessels with small anatomical diameter or in patients after 
endarterectomy.
130
  Moreover, Iemolo et al showed that women have higher frequency 
of apparent stenosis compared to men, who have higher levels of TPA, and men more 
frequently have large artery atherosclerosis at a younger age compared to women.
130
  
This study also showed that TPA was a stronger predictor of stroke, death or 
myocardial infarction than carotid stenosis.   Spence et al showed in the year 2002 that 
carotid atherosclerosis, measured by TPA, is a strong predictor of the combined 
outcome of stroke, heart attack and death.
129
  After adjustment for age, sex, blood 
pressure, serum cholesterol, smoking, diabetes, homocysteine and treatment of blood 
pressure and cholesterol, patients with TPA in the highest quartile (above 1.19 cm
2
) 
had a 3.4 times increased risk of these events as compared to patients in the lowest 
quartile (below 0.12 cm
2
)
129; furthermore patients with TPA≥1.19cm2 have a 20% 5-
year risk of stroke, death or myocardial infarction.
129
  Thus TPA was a much stronger 
predictor of risk than a Framingham or other risk score based on risk factors and can 
be used reliably in all clinical settings (intraclass correlation 0.94).
129, 131
  Moreover, 
the Tromsø study showed that TPA was a strong predictor of stroke,
132
 and a meta-
analysis by Inaba et al showed that TPA was a stronger predictor of MI than intima-
media thickness.
133
  More recently, results from the Northern Manhattan Study, 
U.S.A., showed again that TPA predicts vascular disease.
134
  In that study, Kuo et al 
showed that traditional risk factors explain only a small portion of TPA and 
modification of traditional risk factors is warranted in healthy individuals to decrease 
the risk of a vascular event.
134
  All these studies show that TPA measurements are 
widely available and, consequently, we considered it important to incorporate TPA 
measurement in the diagnosis of large artery atherosclerosis.   
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The last problem that remained unsolved in classification systems before SPARKLE 
was the inclusion of particular risk factors in the diagnosis of specific stroke/TIA 
subtypes.  For instance, the presence of hypertension and diabetes supported the 
diagnosis of small vessel disease.  However, a systematic review by Jackson et al 
showed that diabetes was no longer significant in propensity for small vessel disease, 
among classification systems that did not include risk factors in the definition of 
stroke/TIA subtypes.
135
  Similarly, a meta-analysis by Schulz and Rothwell showed 
that only hypertension and not diabetes was significantly related to small vessel 
disease in population-based studies.
136
  In this meta-analysis, hospitalized patients had 
a higher prevalence of cardioembolic strokes compared to outpatients (28.3% versus 
17.8%, p<0.0001), but a much lower prevalence of small vessel disease (14.3% versus 
27.5%, p<0.0001), respectively.
136
  This was not a limitation in the present study, 
given that SPARKLE is a classification system free from a priori assumptions of the 
role of risk factors in the mechanisms of stroke/TIA subtypes.  A detailed description 
of SPARKLE is provided in the next chapter.   
 
1.8 Relevance of Proposed Research  
To our knowledge, there are no studies analyzing the secular trends of stroke/TIA 
subtypes in a Canadian population for patients who have survived a minor stroke/TIA, 
other than a study in young patients only, which used the TOAST classification 
system.  The study of patients with minor stroke/TIA in an ambulatory setting is of 
particular interest and should be studied separately from hospitalized stroke/TIA 
patients, given that these two populations share different clinical characteristics in 
terms of risk factors, stroke/TIA subtype and severity of stroke.  Patients who have 
suffered only a minor stroke or have recovered completely will have also more to lose 
from recurrent stroke.  Patients who have experienced a minor stroke/TIA are at much 
higher risk of developing an additional and potentially disabling or even fatal stroke, 
and they require intensive investigation and secondary prevention strategies, as 
compared to healthy individuals.  Moreover, the distribution of the risk factors in this 
population is changing over time and the pattern of this change will inform primary 
health care practitioners as to how particular risk factors are changing to improve 
management in areas with suboptimal treatment success.   
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The results of this study will provide evidence on the most common stroke/TIA 
subtypes that warrant specialized medical therapy, improving patients’ prognosis and 
reducing the cost of health care services.  The changing distribution of stroke origins 
is of great importance, because patients with cardioembolic stroke/TIA require 
different treatments (for example, anticoagulant as opposed to antiplatelet agents) to 
prevent recurrent stroke, and require more specialized investigations to detect the 
cardiac source of brain embolism.
137
  A study in Saskatchewan showed that 75% of 
stroke patients required hospitalization due to cardiovascular complications.
138
  This 
increased annual health care costs by $24 million (Canadian) in that Province alone.
138
  
We believe that implementation of more intensive prevention strategies as well as 
increased identification of the most probable mechanism can help reduce this cost.  By 
initiating appropriate treatment early, these funds can be redistributed to more 
intensive prevention strategies as well as more effective therapies.   
At present, there is no up-to-date research in this rapidly changing field in a 
geographically-defined Canadian locale in adults with stroke/TIA other than a study 
exclusively focused on young patients (age<45).
60
  Therefore, our retrospective case 
series study will provide evidence about the change in risk factors and the secular 
trends in stroke/TIA subtypes based on the risk factor-free classification system, with 
the ultimate goal of informing and improving the organization of more effective 
strategies for primary and secondary prevention.  If we indeed find an important 
increase in cardioembolic stroke/TIA, the results of our study will assist health care 
practitioners to place appropriate weight on the need for specialized cardiac 
investigations, and alert them to the need for anticoagulants in a higher proportion of 
patients with stroke/TIA. 
 
1.9 Objectives and Hypothesis of Proposed Research 
 
1.9.1 Primary Objective 
Has there been any change in the secular trends in stroke/TIA subtypes in patients 
with minor stroke/TIA in a Canadian geographically defined area in the past decade? 
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Hypothesis 
We hypothesize that with more intensive management of atherosclerotic risk factors, 
there will have been a decrease in large artery atherosclerosis and small vessel disease 
and, as a consequence, an increase in cardioembolic strokes as a proportion of 
ischemic strokes.  This hypothesis is driven by our anecdotal clinical experience and 
requires systematic, scientific confirmation.  
 
1.9.2 Secondary Objective 
What is the distribution of risk factors for stroke/TIA in patients with minor 
stroke/TIA and separately in each stroke/TIA subtype? 
Hypothesis 
We hypothesize that there will have been an increase in age of patients presenting 
with a first-ever stroke/TIA and an increase in cardioembolic stroke/TIA related to 
atrial fibrillation.  Also, we hypothesize that there will be a decrease in atherosclerotic 
risk factors (hypertension, diabetes mellitus, hyperlipidemia, smoking, etc.) and an 
increase in high and low risk cardiac sources of embolism.  
 
1.9.3 Tertiary Objective 
How valid and reliable is SPARKLE as compared to TOAST and CCS? 
Hypothesis 
We hypothesize that SPARKLE will provide a better diagnosis of stroke cases 
assigning fewer patients to the undetermined category compared to CCS and TOAST.  
As a result, we also expect to have better agreement with CCS as compared to TOAST.
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CHAPTER TWO: PATIENTS AND METHODS  
 
2.1 Overview of Study Methodology 
We performed a retrospective case series study to assess the secular trends in 
stroke/TIA subtypes and their risk factors in the Thames Valley area of Ontario.  Also, 
we used these data to assess the validity and the reliability of the SubtyPes of 
ischAemic stRoKe cLassification systEm (SPARKLE).  In this chapter, we present the 
features of the population from which we retrieved our data and the measurements we 
collected.  We provide a description of SPARKLE and the pilot study we conducted to 
assess the feasibility and the performance of both Causative Classifications System 
(CCS) of acute ischemic stroke and SPARKLE, and discuss our methodology of 
assessing the validity and the reliability of SPARKLE, and the statistical methods 
used for the analysis of our data.   
 
2.2 Study Population 
Canada is divided into 13 Provinces and Territories.  Most of these regions have their 
own stroke network that connects the population to specific centers specialized in 
prevention, acute treatment and continued care of patients inflicted by stroke/TIA.  In 
particular, the Ontario Stroke Strategy divides the Province into 11 geographically 
defined areas to cover all residents living in Ontario, accommodating 24 regional 
secondary prevention clinics.
139
  Each of these areas offers health services to patients 
who have presented with a stroke/TIA to their nearest community hospital, walk-in 
clinic, emergency department or primary care practitioner.  Thereafter, those patients 
who survive a stroke/TIA and are not directly transferred to rehabilitation services 
(patients who had a minor stroke/TIA), receive a referral to a secondary prevention 
clinic, where they are provided with expert management, diagnosis and follow-up of 
their stroke/TIA.   
The Ontario Stroke Strategy was implemented in 2000 and contributed to a significant 
increase in stroke symptoms awareness.
139
  At the same time, in 2000, the Urgent TIA 
Clinic in London, Ontario, began operating.  The Urgent TIA Clinic is the secondary 
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prevention center that covers referrals from the Thames Valley area that includes the 
city of London, Oxford County, Elgin County, Middlesex County, and areas of 
Muncee-Delaware Nation and Chippewa of the Thames First Nation.  However, the 
Ontario Stroke Strategy was established after the year 2002 and, consequently, we 
decided to exclude patients referred to the Urgent TIA Clinic during the first two years 
of the development of this clinical setting to limit selection bias in our retrieved 
patient cases.   
Patients were recruited from the Urgent TIA Clinic, in London, Ontario, where they 
were referred either to Dr. David Spence or Dr. Vladimir Hachinski or another 
attending neurologist.  Our data was collected from patients referred to Dr. Spence, 
because they were all included in the database of the Stroke Prevention & 
Atherosclerosis Research Centre (SPARC).  Appointments were assigned to Dr. 
Spence or Dr. Hachinski by the Urgent TIA clinic receptionist on the basis of the next 
appointment available in a semi-random order and, consequently, there was no 
selection bias.  As a result, our study population is a representative sample of stroke 
survivors who experience a minor stroke/TIA.   
Approximately, 4,500 patients were seen in the Urgent TIA Clinic between the years 
2000 and 2012.  However, in 2000 and 2001 there were only 20 and 123 patients seen 
in our clinic, respectively.  As mentioned above, we decided to exclude these cases 
and compile a database including patients who were diagnosed with stroke/TIA 
between the years 2002 and 2012, at the time when the clinic was better established.  
Moreover, we decided to proceed with data entry based on paper chart review, to 
ensure the minimum possible missing information bias and confirm these information 
with data from the SPARC database.   
Patients with a first-ever stroke/TIA were included in the study and were classified 
based on their medical history, physical examination and laboratory and imaging 
investigations.  Therefore, the sole inclusion criterion of our study population is: 
1. Patients with a confirmed first-ever minor stroke/TIA between the years 
2002-2012. 
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Medical history and investigations data were collected at the first clinical visit.  
Recurrent events were collected as follow-up strokes or follow-up TIAs.  
Clinical information was not collected from patients who were referred to the clinic 
and the stroke expert (Dr. Spence) reported the final diagnosis of stroke mimics (for 
example, focal seizure, brain tumor, subdural hematoma, syncope, peripheral vertigo 
from inner ear diseases, meningioma, brain metastasis, etc.) as well as patients who 
did not attend their appointment.  Consequently, our exclusion criteria are: 
1. Patients with no diagnosis of stroke/TIA, 
2. Patients who did not attend their clinic appointment, 
3. Patients who were seen for a recurrent stroke/TIA and had their first 
stroke/TIA before the year 2002. 
We believe that this is the most appropriate strategy to approach our population study, 
because eligible patients who access any kind of health care services in the Thames 
Valley area, (family physicians, emergency departments or urgent care centers) are 
referred to our facility, and hence, a representative sample of the population study has 
been created to collect data for our analysis.  
 
2.3 Data Sources 
Eligible patients who had a stroke/TIA between the years 2002 and 2012 were 
identified through the administrative office of the Urgent TIA Clinic that receives 
referrals from all patients with acute stroke/TIA in the Thames Valley area and 
confirmed by data from the SPARC database.  A graduate physician (Dr. Bogiatzi) 
performed the data entry of all variables needed for the classification of stroke/TIA 
subtypes (medical diseases related to stroke/TIA).  The diagnosis of stroke/TIA 
subtype was reported previously by the stroke expert (Dr. Spence) who examined the 
clinical cases at the time of their stroke/TIA.  The final categorization of patients into 
one of the five stroke/TIA subtypes relied on the SPARKLE classification system, 
using all available collected information, and was decided in conjunction with the 
stroke expert.   
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Based on the literature review of risk factors and medical diseases related to 
stroke/TIA, the following information necessary for the complete assessment, 
diagnosis and classification of stroke/TIA was retrieved from the paper chart review 
and was entered into an SPSS spreadsheet:  
1. self-reported stroke/TIA risk factors (age, sex, smoking, hypertension, DM, 
hyperlipidemia, AF),  
2. laboratory tests and imaging at the time of the stroke/TIA (glucose, INR, lipids, 
B12, homocysteine, TPA, pack years, blood pressure, CT and/or MRI, Holter, 
transcranial Doppler, carotid Doppler ultrasound, echocardiography),  
3. medications for hypertension, DM, hyperlipidemia, antiplatelet and 
anticoagulant agents,  
4. self-reported past medical history of MI and vascular surgery,  
5. family history of stroke and MI, and,  
6. follow-up events of stroke, TIA, MI, and death.   
Information about diet and physical activity was not collected given that it was based 
on a non-validated questionnaire.  Moreover, race was not collected as it was not 
provided in the clinical notes.   
 
2.4 Measurements of Collected Variables 
Age and year of event: Age and year were entered as continuous variables 
corresponding to the patients’ age at the time of their first cerebrovascular event.  The 
date of this event was also recorded.  
Sex: Men and women were recorded using a code of 0 and 1, respectively. 
Smoking and pack-years: Self-reported smoking status (never smoked, quit 
smoking>1year ago, active smoker) as well as total exposure to smoke, measured as 
pack-years, were assessed in all patients with the same set of questions by the stroke 
expert and the technologists who performed the carotid ultrasound.  
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Medical history of hypertension, DM, hyperlipidemia and AF:  A history of each of 
these risk factors was collected as a discrete variable, based on the self-reported or 
referral report of presence of newly diagnosed or earlier known hypertension, DM, 
hyperlipidemia and AF.  This information was confirmed based on the use of 
medications to treat the aforementioned medical conditions.   
Glucose and International Normalized Ratio (INR): Laboratory measurements of 
glucose and INR were collected from reports of the emergency department.   
Total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, B12, total 
homocysteine: Laboratory measurements were ordered at the first clinical assessment 
of patients at the Urgent TIA clinic and the results were collected and entered as 
continuous variables.   
Carotid ultrasound, TPA and blood pressure: Before the first clinical assessment at 
the Urgent TIA Clinic, all patients underwent ultrasound assessment of carotid 
stenosis and measurement of TPA, as well as measurement of systolic and diastolic 
blood pressure with a regularly calibrated automated blood pressure manometer.   
Brain imaging (CT, MRI): Investigation of brain imaging was either collected from 
the emergency department reports or was ordered at the first visit at the Urgent TIA 
Clinic and was entered as a discrete variable, based on the presence of acute and/or 
chronic infarction or normal imaging.   
Cardiac evaluation:  Echocardiogram and holter monitoring was ordered at the Urgent 
TIA Clinic in patients whose medical history and physical examination suggested a 
cardiac source of embolism. Electrocardiograms were available in all patients 
presented to an emergency department.   
Treatment of hypertension, DM, hyperlipidemia: Type of medications used before the 
first cerebrovascular event was collected on history or after a contact with their 
pharmacy.  The use of medication for each medical condition was entered as a discrete 
variable as in “Yes/No”.   
Antiplatelet and anticoagulant agents: The use of antiplatelet or anticoagulant agents 
within a month before a stroke or TIA was collected from the medical history or their 
pharmacy, and was entered as a discrete variable.   
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Past medical history of MI and vascular surgery: Self-reported or referral report of 
past medical history of MI and past vascular surgery was collected at the first visit at 
the Urgent TIA Clinic and was entered as a discrete variable.   
Family history of stroke and MI: Self-reported or referral report of family history of 
stroke and MI was collected at the first visit at the Urgent TIA Clinic and was entered 
as a discrete variable.   
Follow-up events: Information about stroke, TIA, MI and death at the time following 
the first stroke/TIA was collected from paper chart review and was entered as a 
discrete variable.  
Population coverage of Urgent TIA Clinic: Information about the number of residents 
living in the coverage areas of the Urgent TIA Clinic was collected from the Census 
reports of the years 2001, 2006 and 2011 from Statistics Canada and was entered as a 
continuous variable.  Population estimates are presented in Appendix C.   
 
2.5 Classification System 
As mentioned in the introduction, SPARKLE was used for the classification of 
stroke/TIA in our study.  This classification was adapted from the existing CCS 
classification system.
128
  In SPARKLE, we included TPA measurements of large 
artery atherosclerosis, currently used in clinical practice,
129
 and we revised the CCS 
criterion of parallel testing for imaging investigation for all patients with stroke/TIA.  
Based on CCS, imaging of the brain, cardiac imaging and evaluation of intracranial 
and extracranial arteries are all necessary to classify an “evident” cause of stroke/TIA.  
Alternatively, in the absence of one of the aforementioned investigations, CCS 
classified an otherwise “evident” cause of stroke as “possible” cause within the same 
stroke/TIA subtype.  Likewise, when at least one of the investigations was missing, a 
“possible” cause is classified as “incomplete evaluation” in CCS, which falls under 
the “undetermined cause of stroke” category.  However, in our practice, parallel 
testing using brain imaging (CT and/or MRI), ECG, carotid ultrasound and basic 
blood test was used to differentiate between stroke mimics and cerebrovascular events 
at baseline, and additional laboratory investigation as serial testing was guided by the 
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medical history and the physical examination.  The inclusion of baseline carotid 
ultrasound in all patients helped reduce selection bias of patients who will be chosen 
to have additional investigation (based on a more thorough clinical assessment by the 
stroke expert) by providing evidence to differentiate between different stroke/TIA 
subtypes (for example, differentiate between large artery atherosclerosis and carotid 
dissection).  Consequently, there were patients who had no indication for cardiac 
imaging, angiography or complete intracranial and extracranial vascular evaluation.  
These criteria provide a classification system that is highly sensitive in diagnosing a 
cerebrovascular event (based on baseline parallel testing) and highly specific and cost 
effective in differentiating between particular stroke/TIA subtypes (based on the 
additional serial testing).  “Incomplete investigation” was assigned to patients who 
had indication for additional investigation of their cause of stroke and they did not 
attend their appointment or an appointment for further investigation was not scheduled.   
In the presence of more than two “evident” causes of stroke/TIA, we classified the 
most “probable” stroke/TIA subtype, in contrast to CCS, where patients with more 
than two evident causes are classified as “undetermined etiology”.  Also, cases that 
had more than one “possible” cause of stroke/TIA were classified according to the 
“possible” stroke/TIA subtype that is more likely to be related to the presenting 
stroke/TIA, whereas in CCS, cases with more than one “possible” etiology are simply 
classified as being of “undetermined etiology”.  The assignment of cases in the most 
“probable” or most “possible” cause of stroke/TIA was based on information from the 
patients’ history showing a close-in-time relationship between the onset of a stroke-
related medical condition to the onset of stroke/TIA symptoms and a mechanism of 
disease explaining the presenting stroke/TIA (for example, new onset of AF and 
multiple territory stroke/TIA leads to the diagnosis of cardioembolic stroke/TIA, 
motor-vehicle accident and carotid or vertebral dissection leads to the diagnosis of 
stroke/TIA of other rare or unusual cause).  All clinical cases that had an unclear final 
diagnosis of their stroke/TIA, with information from the medical history and findings 
from the physical examination that did not match together, were reviewed during 
regular meetings with the stroke expert (Dr. Spence).  In these meetings, all elements 
from medical history, physical examination, laboratory investigation and test results 
were reviewed in order to assign the most relevant stroke/TIA subtype.  
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The final stroke/TIA subtype was assigned to our cases when the clinical assessment 
and basic laboratory tests were able to reach to a definitive diagnosis, by ruling out 
medical conditions that mimic vascular etiologies.  We investigated this by testing the 
consistency of the diagnosis between baseline and one year follow-up.  We believe 
that our classification system can become useful to enhance current clinical practice 
and be applied elsewhere, since it reflects “real world” clinical management.  
 
SPARKLE consists of five categories of stroke/TIA subtypes:  
1. large artery atherosclerosis,  
2. cardioembolic,  
3. small vessel disease,  
4. other rare or unusual etiology, and 
5. undetermined etiology.   
We categorized cases into each stroke/TIA subtype based on information from the 
medical history and physical examination, as well as results of brain and vascular 
imaging, and subsequently we confirmed or altered our clinical suspicion based on the 
results of additional laboratory diagnostic tests (for example, confirm the presence of 
a cardioembolic stroke/TIA when results from the echocardiogram show a cardiac 
source of embolism).  Below, we present the criteria for each ischemic stroke subtype.   
 
Large Artery Atherosclerosis Stroke/TIA 
Clinical aspects:  These patients present with fluctuating symptoms that vary between 
normal and gradual worsening with varying periods of improvement.  Symptoms 
involve disability related to cerebral or cortical dysfunction (asymmetric motor or 
sensory impairment, aphasia, etc.) or to brain stem or cerebellar dysfunction.  At the 
physical examination, a carotid bruit may be present.
140
  Clinical symptoms of 
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Subclavian Steal Syndrome can be present.
141
  Cardiac sources of embolism must be 
excluded.   
Laboratory properties:  Brain imaging can indicate cortical, cerebral or cerebellar 
infarction ≥2cm in diameter on CT or MRI; in TIA normal brain imaging is expected.  
Additional investigations include carotid Doppler ultrasound and/or angiography to 
assess presence of atherosclerotic lesions and significant stenoses.  Ultrasound 
evidence of clinically relevant Subclavian Steal Syndrome denotes “evident” 
diagnosis of large artery atherosclerosis.
141
   
Evident etiology:  The final etiology of these cases is significant, ipsilateral internal 
carotid or intracranial artery stenosis of ≥50%, or TPA≥1.19cm2 with no evidence of 
acute infarction in vascular territories other than the symptomatic vascular territory.
128, 
129
  Amaurosis Fugax can be present.  Clinically relevant imaging confirmation of 
Subclavian Steal Syndrome and ipsilateral Microemboli detection on TCD monitoring 
denote presence of symptomatic large artery atherosclerosis disease.
141-143
   
Probable etiology:  Medical history suggesting Amaurosis Fugax or previous 
undiagnosed TIA, all occurring in the same vascular territory, with evidence of 
hemodynamically significant and ipsilateral internal carotid or intracranial artery 
stenosis of ≥50%, or TPA≥1.19cm2 within a month before symptom onset.  Additional 
presence of “evident” causes of different stroke/TIA subtypes are present and are well 
controlled with a mechanism of disease unrelated to the presenting stroke/TIA.   
Possible etiology:  Presence of low-risk atherosclerotic plaque causing mild ipsilateral 
internal carotid or intracranial artery stenosis <50%, or 0.12cm
2≤TPA<1.19cm2 
without evidence of any other “possible” cause of stroke/TIA or in the presence of 
another “possible” cause of stroke/TIA that is well-controlled within a month before 
symptom onset and with a mechanism of disease unrelated with the presenting 
stroke/TIA.   
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Cardioembolic Stroke/TIA 
Clinical aspects:  These patients present with acutely developed cerebral or cortical 
symptoms of increased severity at the onset of the event with rapid clinical 
improvement.
144
  Symptoms and signs can indicate involvement of multiple vascular 
territories (involvement of both anterior carotid circulations, or both anterior carotid 
and posterior vertebrobasilar circulations), based on information from the medical 
history and/or the physical examination, respectively.
128, 145
   
Laboratory properties: Patients with stroke have brain imaging (CT and/or MRI) 
indicating cerebral or cortical infarction; brain imaging is normal in patients with TIA.  
Echocardiogram (TTE and/or TEE) investigates high and/or low risk cardiac source of 
embolism (Table 1).
128, 146
  Holter monitoring of the heart rhythm is indicated where 
cardiac arrhythmia is suspected.  Transcranial Doppler (TCD) bubble test confirms 
right-to-left cardiac shunt in the case of immediate presence of bubbles in the TCD of 
middle-cerebral artery (MCA) or pulmonary arterial-venous malformation (AVM) in 
the presence of delayed bubbles.
147-149
  Carotid ultrasound excludes presence of large 
artery atherosclerosis. 
Evident etiology:  Patients present with multiple territory acute infarcts in CT or MRI, 
or normal brain imaging with symptoms related to multiple territory transient 
symptomatology, or evidence of systemic embolism in the presence of a high risk 
cardiac source of embolism (Table 1).
128, 146
  These patients can also have clinical 
clues to paradoxical embolism, with evidence suggesting pulmonary embolism or 
deep vein thrombosis at the time of their stroke/TIA, and confirmation of cardiac 
sources of embolism on echocardiography, or TCD bubble study.
150
  
Probable etiology:  Patients present with acute multiple infarcts and involvement of 
different vascular territories or systemic embolism at the time of their stroke/TIA or 
within a month before symptom onset.  Additional “evident” causes of different 
stroke/TIA subtypes are present, but are unrelated in time to the onset of the 
presenting stroke/TIA.   
Possible etiology:  Multiple territory symptomatology with evidence of clinical clues 
to paradoxical embolism and negative echocardiogram or transcranial bubble study 
Doppler.  Presence of low risk cardiac sources of embolism (Table 1).
128, 146
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Investigation can reveal presence of additional “possible” causes of different 
stroke/TIA subtypes, unrelated in time and in terms of mechanism of disease with the 
presenting stroke/TIA.   
 
Small Vessel Disease Stroke/TIA 
Clinical aspects:  These patients have acute onset of symptoms compatible with one 
of the five described “lacunar syndromes”: pure motor hemiparesis, pure sensory 
stroke, ataxic hemiparesis, sensorimotor stroke, dysarthria-clumsy hand syndrome 
(Table 2).
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  Medical history and physical examination should exclude cardiac sources 
of embolism and ipsilateral high-risk large artery atherosclerosis.
151
   
Laboratory properties:  Brain imaging: deep brain infarction ≤2cm in diameter on CT 
or MRI without focal stenosis or other vascular pathology (e.g., dissection, vasculitis, 
etc.) in the main artery providing blood to the penetrating arteries, and without cortical 
or cerebral dysfunction.
128
  Normal imaging can be present in patients with TIA.  
Carotid ultrasound excludes large artery atherosclerosis disease or high grade stenosis.  
Echocardiography excludes cardiac sources of embolism.   
Evident etiology:  Presence of one of the five described “lacunar syndromes” with 
imaging and clinical evidence of deep brain infarction.  Normal or low risk carotid 
Doppler ultrasound (0.12cm
2≤TPA<1.19cm2), or low risk cardiac source of embolism 
can be present, but are unrelated in time with stroke/TIA symptoms onset.   
Probable etiology:  Presence of a “lacunar syndrome” with presence of at least one 
more “evident” cause of a different stroke/TIA subtype.   
Possible etiology:  Clinical evidence of a “lacunar syndrome” with normal brain 
imaging.  Additional investigation can bring to light “possible” causes of different 
stroke/TIA subtypes, unrelated with presenting stroke/TIA in time and in terms of 
mechanism of disease.   
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Other Rare or Unusual Cause of Stroke/TIA 
Clinical aspects:  These patients may have evidence of event onset after traumatic 
overextension of the neck or forced movement (e.g. chiropractic neck manipulation), 
or after medical intervention involving the heart or other parts of the vascular 
circulation.  Alternatively, there may be clinical evidence of rare genetic or 
hematological disorders, causing increased blood viscosity or any other rare or 
unusual medical condition (Table 3).
128
   
Laboratory properties:  Based on the medical history and the physical examination, 
the following diagnostic tests are used to confirm the diagnosis, where applicable: 
Carotid Doppler ultrasound and/or angiography to differentiate arterial dissection 
from large artery atherosclerosis disease, blood tests for genetic or hematological 
disorders, urine drug testing, etc.  Investigations for cardiac sources of embolism are 
ordered (e.g. echocardiography) to rule out cardiac sources of embolism.   
Evident etiology:  Laboratory confirmation of a rare or unusual cause of stroke/TIA or 
mechanism of disease occurring immediately preceding symptom onset (e.g. 
dissection, etc.). 
Probable etiology:  Medical history suggesting mechanism of unusual or rare disease 
closely related in time with present stroke/TIA, in the presence of other “evident” 
etiologies of stroke/TIA (for example, evidence of vertebral dissection after traumatic 
neck injury in the presence of TPA≥1.19cm2 or atrial fibrillation, etc.).   
Possible etiology:  Medical history supporting a rare or unusual cause of stroke/TIA, 
with negative investigations (e.g., forced neck movement suggesting acute arterial 
dissection with negative ultrasound or angiography a few weeks after the event).   
 
Undetermined Cause of Stroke/TIA 
Clinical aspects:  Patients with evidence of stroke/TIA on the physical examination 
and brain imaging or evidence of TIA on the medical history with normal laboratory 
investigation.  These patients present with symptoms and clinical signs not explained 
by one of the aforementioned categories.   
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Laboratory properties:  Brain imaging (CT and/or MRI) may indicate presence of 
stroke or is normal in patients with TIA.  Further investigations including carotid and 
TCD ultrasound, echocardiogram and/or Holter, blood tests for rare or unusual genetic 
or hematologic disorders are within normal limits. 
Unknown etiology:  Patients present a medical history that cannot suggest any 
possible mechanism of disease.  In the case of clinical characteristics suggestive a 
specific mechanism of disease, initial and additional investigations return normal 
results.   
Incomplete Evaluation:  Positive medical history for one of the four aforementioned 
categories, with lack of appropriate investigations (e.g., medical history and physical 
examination favouring a given stroke/TIA subtype with absence of supporting 
investigations).   
 
2.6 Pilot Study and Results 
We created a final database of approximately 4,350 cases using records from the 
Urgent TIA Clinic with all patients diagnosed with stroke/TIA between the years 
2002-2012.  To ensure feasibility of data collection and analysis within a year of the 
study period, we reviewed the first 476 clinical cases of our database using SPARKLE 
and CCS, and classified cases eligible to participate in the study including all 
aforementioned variables.   
 
The main objectives of the pilot study were:  
1. to determine the time needed for chart review and collection of all variables,  
2. to determine the applicability of the two classification systems (CCS, 
SPARKLE) in our clinical practice, by comparing the assignment of cases into 
stroke/TIA subtypes with previous studies in different countries, and 
3. to determine the agreement between CCS and SPARKLE.   
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Eligible cases were included based on the inclusion and exclusion criteria of the 
retrospective case series study.  Among the first 476 reviewed cases, 76 were 
excluded because they did not have a diagnosis of stroke/TIA or did not attend their 
appointment or had a first-ever stroke/TIA before the year 2002.  The remaining 400 
classified cases were analyzed and a random sample of approximately 50 charts 
among the classified 400 cases was selected for review with the stroke expert (Dr. 
Spence) to confirm the assigned stroke/TIA subtype and to ensure quality of data 
entry.  Cases with unclear stroke/TIA diagnosis were also assessed with the stroke 
expert to decide the most relevant stroke/TIA subtype.   
Case review for the pilot study began in May, 2012.  We received the approval of the 
study from the Western University Research Ethics Board in January, 2012.  A 
graduate physician (Dr. Bogiatzi) was trained between January and April 2012 in 
chart review and application of both classification systems of approximately 100 cases 
diagnosed with stroke/TIA between the years 2000 and 2001.  Information about 
stroke/TIA subtype from the cases presented in 2000 and 2001 that were used during 
the training period (January-April 2012) were not entered in the final analysis, as 
patients referred to the Urgent TIA clinic between 2000 and 2001 were excluded from 
our study, as mentioned previously.   
Time interval between review of the first and the last clinical chart until completion of 
the 476 charts was recorded.  Simple descriptive statistics and the exact McNemar’s 
test were used to compare stroke/TIA subtypes in dependent cases classified twice 
based on CCS and SPARKLE.  Cohen’s Kappa statistics was used to assess the 
agreement between CCS and SPARKLE.   
The duration of the pilot study was three weeks in total, denoting that double time is 
probably needed to complete data entry using both classification systems.  The 
categorization of stroke/TIA patients using SPARKLE and CCS showed significant 
differences between the two classification systems, in all stroke/TIA subtypes (Table 
4).  We recorded fair agreement between SPARKLE and CCS (Cohen’s Kappa 0.39). 
The results of our pilot study show that CCS has poor applicability in our clinical 
practice.  Patients who had cardioembolic stroke/TIA rarely had intracranial vascular 
assessment and patients who had large artery atherosclerosis frequently didn’t undergo 
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cardiac assessment, unless there was a specific indication (for example, multiple 
territory stroke) for the aforementioned tests to be ordered.  Using CCS and in the 
absence of complete investigation, 76% of the cases were registered under the 
“Undetermined” stroke/TIA subtype, and of these, 68% cases had “Incomplete 
Evaluation” that could not be realistic in the case of our clinical practice.  Similar high 
scores in assignment of cases under the “undetermined etiology” of stroke/TIA have 
been reported previously by Sagui et al
152
 in Dakar, Africa, where there was a great 
shortage in medical imaging and laboratory equipment, which is totally different from 
the current clinical practice in Canada.  However, using SPARKLE, only 23.8% of the 
cases were classified as “Undetermined”, which is in line with results from previous 
studies in other countries that used classification systems developed before 
SPARKLE.
29, 31, 32, 35, 48, 56, 58, 153-155
  For the same reason, the majority of cases in CCS 
were regarded as “possible” causes of stroke/TIA, whereas there was a broad 
distribution across all the three subgroups within each subtype by using SPARKLE 
(Appendix B).  Consequently, we performed data entry using SPARKLE as the most 
germane classification system with accurate application to our practice.   
 
2.7 Methodology of Validation and Reliability Study 
To validate SPARKLE with antecedent classification systems (CCS and TOAST), we 
performed a best-case scenario comparison of cases.  We decided to include only 
cases that could be fully classified with CCS, in order to accurately compare the 
results with SPARKLE.  It is worth noting that one-fourth of our classified clinical 
cases (880 cases from the cohort of 3,445 patients) fulfilled complete diagnostic 
investigation of the vascular system based on CCS, and our random sample was 
retrieved within the cases that satisfied CCS criteria.   
A random sample of 25 cases per year was selected from this subgroup of our cases 
that had intracranial and extracranial vascular evaluation and cardiac testing.  The 
final retrieved sample of 275 cases was entered in a new dataset, in which all 
investigations and measurements of risk factors were retained.  The initial 
categorization into stroke/TIA subtypes was removed to ensure unbiased testing of 
validity and reliability.   
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Cases were independently assessed by a graduate physician (Dr. Bogiatzi) and a 
medical graduate research fellow physician (Dr. Wannarong), who both classified the 
275 cases according to SPARKLE to measure intra-rater and inter-rater reliability, 
respectively.  The selected cases were classified again by the graduate physician (Dr. 
Bogiatzi) according to CCS and TOAST classification system, to measure the 
agreement with SPARKLE and follow-up events were classified based on SPARKLE 
and CCS.  Finally, SPARKLE was determined again at one year follow-up after the 
first stroke/TIA, to measure the consistency of the initial classification within a year 
after the first stroke/TIA.   
 
2.8 Sample Size Calculation for Validation Study 
Based on the results of our pilot study, we calculated the sample size needed to 
validate SPARKLE against CCS and TOAST and to achieve 80% power at the level 
of significance α=0.05.  Given that cardioembolic stroke/TIA was the most common 
subtype, we calculated the sample size with a proportion of cardioembolic stroke/TIA 
of 11.3% (according to CCS) and an expected proportion of 45.8% (according to 
SPARKLE) based on the results of our pilot study, and we found that we would need 
52 individuals to have 80% power to detect significant differences between CCS and 
SPARKLE at α=0.05.  We repeated again the calculations for CCS and TOAST using 
information from patients with cardioembolic stroke in TOAST Trial (21%) and 
45.9% in CCS study (45.9%).
127, 156
  Based on these proportions, we would need 112 
individuals to have 80% power to identify differences at the level of significance 
α=0.05.  Also, given the availability of all the data, we retrieved a random sample of 
25 cases per study year.  As a result, with the final 275 individuals, we will have more 
than 80% power to detect differences between the three classification systems 
(SPARKLE, CCS, TOAST).  To confirm the adequacy of our sample size, we 
repeated the calculation using as a reference the population-based study by Palm et 
al,
157
 which showed that the predominance of cardioembolic strokes was 35%, as well 
as the study by Ay et al
156
 that proposed CCS as a classification system and showed 
that 45.9% of strokes were cardioembolic.  Therefore, to be within 10% of the true 
proportion of cardioembolic strokes and to maximize the proportion at p=0.50, we 
would need 96 individuals to produce a 95% confidence interval estimate for the 
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proportion of patients with cardioembolic stroke with a margin of error of 10%, and 
this would be an adequate sample size for all other stroke/TIA subtypes.
158
   
 
2.9 Statistical Analysis 
Quality of entered data was assessed using scatter plots for the continuous variables.  
All cases of unexplained outliers were re-evaluated comparing the information with 
paper chart documents, and erroneous data entry was corrected.  Descriptive statistics 
were used to explore the distribution of risk factors in each stroke/TIA subtype in both 
sexes and in each year of the study.  Continuous data were analyzed with analysis of 
variance (ANOVA) and discrete data were analyzed with Chi-Square statistics.   
Secular trends in stroke/TIA subtypes using SPARKLE for all cases in the cohort 
were analyzed using a Poisson regression model, which is a form of “count regression 
analysis” appropriate for positive counts of the number of patients presenting with 
stroke/TIA during every clinic day.  We plotted for each stroke/TIA subtype a lattice 
plot
159
 counting all patients presenting with each stroke/TIA subtype per clinic day 
(yt=counts of patients presenting with each stroke/TIA subtype).  We calculated the 
number of days from January 2002 until December 2012 and called this variable 
"clinic day number" (t=“clinic day number” or “Julian day number”), which serves as 
the response variable in our Poisson regression model [yt ~ Po(μt)].
160
  Secular trends 
were assessed using a fitted cubic spline function of the “clinic day number”[log (μt) – 
fitted cubic spline function of t], which is a smoothing function that divides the 
plotting of our data into separate periods with similar trends of increasing or 
decreasing counts of observations and provides the overall trend of all plotting data.
161
  
For each of the five different subtypes of stroke/TIA, we computed the total counts of 
females, of males and of both sexes and implemented a Poisson regression model with 
spline trend function that is testing the null hypothesis that there is no trend in the data.  
This model was tested for serial correlation in the deviance residuals.  In the case of 
autocorrelation, the p-values of the Poisson regression model with the spline function 
were compared to the Mann-Kendall trend test with blocked boodstrap,
162, 163
 which is 
a widely used test for monotonic simple linear trend model testing the null hypothesis 
that the data are independent and identically distributed.  The Mann-Kendall trend test 
 38 
with blocked bootstrap tests the null hypothesis of stationary time series versus the 
alternative hypothesis that there is a monotonic trend with random autocorrelated 
errors.  Negative serial correlation implies that p-values in regression are 
conservative.
164
  This means that the p-values in Mann-Kendall trend test are more 
significant as compared to Poisson regression analysis with spline trend function in 
the presence of negative autocorrelation (the opposite applies in the presence of 
positive autocorrelation).  All p-values were two sided and were considered significant 
if p<0.05.  Bonferroni correction was used to control for multiple testing.   
A logistic regression model with stepwise procedure was used to assess the relation of 
risk factors with each stroke/TIA subtype.
158
  Risk factors were initially assessed for 
collinearity.  Based on literature review, age, sex and BMI were analyzed as 
confounders; therefore, we stratified our population in age groups (<40, 40-50, 50-60, 
60-70, 70-80, >80), in obese and normal weight individuals (BMI≥25, BMI<25, 
respectively) and in men and women.  Only main effects were investigated in this 
thesis.  It is likely that there could be some interesting interactions but their study and 
elucidation is beyond the scope of this thesis.   
To assess construct validity, results from the comparison of the three classification 
systems (SPARKLE, CCS, TOAST) were analyzed using McNemar’s test for the 
comparison of discordant cases in the dependent cases classified multiple times to 
compare SPARKLE and CCS, as well as SPARKLE and TOAST.
165
  Moreover, 
Cohen’s kappa statistic was used to assess the agreement of SPARKLE with CCS and 
TOAST.  Cohen’s kappa was also used to measure the agreement between the two 
raters and derive the intra-rater and the inter-rater reliability of SPARKLE.
166
   
According to the kappa statistics, the strength of agreement was interpreted based on 
Landis and Koch criteria
167
 as: 
 Poor agreement (κ-value < 0.00) 
 Slight agreement (κ-value = 0.00 – 0.20) 
 Fair agreement (κ-value = 0.21 – 0.40) 
 Moderate agreement (κ-value = 0.41 – 0.60) 
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 Substantial agreement (κ-value = 0.61 – 0.80) 
 Almost Perfect Agreement (κ-value > 0.80) 
Simple descriptive statistics were analyzed with IBM SPSS Statistics version 20.
168
  
Trend analysis, McNemar’s test and regression analysis was performed using R for 
Windows, Version 2.15.2.
169
  
 
2.10 Additional Analysis 
We measured agreement between the initial classification and the assignment of cases 
one year after the first stroke/TIA using the same SPARKLE criteria to assess 
consistency and predictive validity in light of additional results from more laboratory 
investigation at one year follow-up.  Moreover, recurrent stroke/TIA (irrespective of 
the time of the events) was also classified based on SPARKLE and CCS and 
agreement between first and recurrent events was calculated.  Differences between 
cases that had recurrent events and those who did not, was assessed using Chi-square.   
 
2.11 Ethics Approval 
This study commenced soon after the approval of our application from the Office of 
Research Ethics of Western University.  All data were already in existence.  There 
was no contact with patients, nor any additional testing.  All variables had been 
collected as part of routine clinical care.  There was no potential for physical, 
psychological, emotional, social or economic harm to patients in these analyses of 
existing data, and participants will remain anonymous in subsequent reports and 
publications.   
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Table 1. Cardiac Sources of Cerebrovascular Embolism
128, 146
 
High Risk 
Cardiac 
Sources 
of 
Embolism 
Left Atrial Thrombus 
Left Ventricular Thrombus 
Atrial Fibrillation (AF) 
Paroxysmal Atrial Fibrillation 
Sustained Atrial Flutter 
Recent Myocardial Infarction (within 1 month) 
Chronic Myocardial Infarction with ejection fraction <28% 
Symptomatic Congestive Heart Failure with ejection fraction <30% 
Ventricular Dyskinesia or Hypokinesia in Echocardiogram 
Rheumatoid Mitral or Aortic Valve Disease 
Bioprosthetic or Mechanical Heart Valve 
Nonbacterial Thrombotic or Infective Endocarditis 
Papillary Fibroelastoma 
Left Atrial Myxoma 
Left Ventricular Aneurysm or PFO with clinical clues to paradoxical 
embolism* 
Low Risk 
Cardiac 
Sources 
of 
Embolism 
Mitral Annular Calcification and/or Aortic Valve Calcification 
Atrial Septal Aneurysm without Shunt 
Left Ventricular Aneurysm without Thrombus or PE or DVT 
Isolated Left Atrial Smoke, without Mitral Stenosis or AF 
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Mitral Valve Prolapse 
Complex Atheroma in the Ascending Aorta or Proximal Arch 
Clinical clues to paradoxical embolism with negative imaging for shunt* 
PFO: Patent Foramen Ovale 
DVT: Deep Venous Thrombosis 
PE: Pulmonary Embolism 
*Clinical clues to paradoxical embolism: young patient with no other defined cause of 
stroke, with a history of DVT or PE, Valsalva maneuver at the onset of the 
cerebrovascular event, recent prolonged travel or sitting or immobilization, waking up 
with stroke symptoms, sleep apnea, shortness of breath during the cerebrovascular 
event, loud pulmonary regurgitation murmur (P2), varicose veins, asymmetric swollen 
legs, DVT or PE in the past.
150
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Table 2. Clinical Signs and Symptoms of Small Vessel Disease Stroke/TIA
22
 
Lacunar syndrome Clinical signs and symptoms 
Pure Motor Unilateral paresis/paralysis of face, arm and leg 
Pure Sensory Unilateral numbness of face, arm and leg 
Ataxic Hemiparesis Unilateral motor paresis/paralysis and limb ataxia 
Sensorimotor Ipsilateral motor and sensory impairment of face, arm and leg 
Dysarthria-clumsy 
hand syndrome 
Unilateral motor impairment of face and hand with hand 
clumsiness and with dysarthria and dysphagia 
 
 
Table 3. Other Defined Rare or Unusual Causes of Stroke/TIA
128
 
Acute or Chronic Arterial Dissection 
Acute Disseminated Intravascular Coagulation 
Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) 
Cerebral Venous Thrombosis/Cerebral Sinus Thrombosis/Retinal Vein 
Occlusion 
Arteritis (Giant Cell, Necrotizing or Granulomatous), Vasculitis
144
 
Clinically Relevant Aneurysm 
Drug-Induced Stroke 
Fibromuscular Dysplasia 
Meningitis 
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Migraine-Induced Stroke 
Segmental Vasoconstriction or Vasospasm 
Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-Like 
Episodes 
Moyamoya Disease  
Fabry Disease 
Primary Antiphospholipid Antibody Syndrome or Sneddon Syndrome 
Primary Infection of the Arterial Wall 
Sickle Cell Disease, Polycythemia Vera, Essential Thrombocytosis, 
Acute or Chronic Leukemia  
Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome 
Connective Tissue Disorders (e.g., Scleroderma) 
Beauty Parlor Stroke Syndrome, Chiropractic stroke or Hangman’s 
Fracture 
Hypoperfusion Syndromes (e.g., sepsis, medications, etc.) 
Iatrogenic Causes (e.g., stroke after coronary artery bypass graft surgery, 
other vascular intervention, etc.) 
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Table 4. Pilot Study Results Comparing Stroke/TIA Subtypes Between 
SPARKLE and CCS.   
 SPARKLE CCS p-value 
 n % n %  
Large Artery Atherosclerosis 75 19 34 9 <0.001 
Cardioembolic 183 46 45 11 <0.001 
Small Vessel Disease 37 9 13 3 <0.001 
Other Causes 10 3 3 1 0.008 
Undetermined Causes 95 24 305 76 <0.001 
Total 400  400   
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CHAPTER THREE: RESULTS 
 
3.1 Baseline Population Characteristics and Ischemic Stroke Subtypes 
Among the 4,350 cases in our database, approximately 500 cases were excluded based 
on our exclusion criteria.  In addition, 400 paper charts equally distributed in all study 
years were probably shredded or misallocated and could not be found; consequently, 
these 400 cases were removed from our database.   
A total of 3,445 consecutive patients with first-ever stroke/TIA between the years 
2002-2012 were studied with mean age±SD of 65±15.  There were 1,693 men (49.1%) 
and 1,753 women (50.9%) with mean age±SD of 65±14 and of 65±16, respectively 
(p=0.442).  Baseline population characteristics are provided in Table 5.  
At the time of referral, 77% of patients with a new or old diagnosis of hypertension 
were treated with blood pressure lowering medications, and similarly, 74% of patients 
with new onset and known DM were on oral or injectable medications for controlling 
hyperglycemia.  Also, 50% of patients with newly diagnosed or known high levels of 
cholesterol and triglycerides were treated with lipid lowering medications.  Finally, 
50% of patients with known or newly diagnosed AF were treated with anticoagulant 
agents.  In total, among the 307 patients with AF, 153 patients were treated with 
anticoagulant agents and 25 patients were on antiarrhythmic medications.  Among 
those who had AF and for whom we were able to obtain INR measurements (186 
patients), 121 patients were treated with anticoagulant agents and 76 of them (63%) 
were in the therapeutic range, with INR≥2.   
Concerning the distribution of stroke/TIA subtypes, 1,132 (33%) patients had large 
artery atherosclerosis, 1,298 (38%) patients had cardioembolic, 354 (10%) patients 
had small vessel disease, 221 (6%) patients had other rare or unusual causes, and 440 
(13%) patients had an unknown cause of stroke/TIA.   
In patients with cardioembolic stroke/TIA, 454 patients had PFO and clinical clues of 
paradoxical embolism such as evidence of deep venous thrombosis or pulmonary 
embolism, 108 patients had echocardiographic evidence of cardiac wall abnormalities 
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related to MI, 253 patients had AF and 118 of them (47%) were treated with 
anticoagulant agents.  For patients with cardioembolic stroke/TIA and AF for whom 
we had INR measurements (150 cases), only 51 of them  achieved INR≥2 (Table 6).  
The remaining cases had low risk cardiac sources of embolism.   
In patients with cardioembolic stroke/TIA, there was a steady presentation of patients 
with AF (23 patients in the year 2002 vs. 21 patients in the year 2012), but there was a 
significant increase in Holter monitoring, from 73 tests ordered in the year 2002, as 
compared to 147 Holter tests in the year 2012 (p<0.05).  Also, more patients with 
cardioembolic stroke/TIA and AF were treated with anticoagulant agents in more 
recent years, but not all of these patients achieved adequate treatment with INR≥2 
(Table 6).  There was no significant difference in homocysteine levels in patients with 
cardioembolic stroke/TIA and AF (p=0.2) between the years 2002-2012.  However, 
there was a significant increase in high or low risk cardiac sources of embolism on the 
echocardiogram from 43 cases in the year 2002 to 73 cases in the year 2012, and also 
a significant increase in echocardiograms from 73 in the year 2002 to 147 in the year 
2012.  Finally, there was an increase in patients presenting with PFO and clinical clues 
or evidence of paradoxical embolism, from 25 in the year 2002 to 58 in the year 2012.   
In all patients with cardioembolic stroke/TIA, 47% of patients had an “evident” cause 
of stroke/TIA, 20% of patients had multiple and, therefore, a “probable” cause of 
stroke/TIA and 33% of cases had a “possible” cause of stroke/TIA.  Among patients 
with large artery atherosclerosis, 72% of patients had an “evident”, 12% of patients 
had a “probable”, and 16% of patients had a “possible” cause of stroke/TIA.  In 
patients with small vessel disease, 26% of patients had an “evident”, 31% of patients 
had a “probable”, and 42% of patients had a “possible” cause of stroke/TIA.  In 
patients with other rare or unusual causes of stroke, 29% of patients had an “evident”, 
15% of patients had a “probable”, and 56% of patients had a “possible” cause of 
stroke/TIA.  Finally, among patients with undetermined causes of stroke/TIA, 81% of 
patients had an unknown cause of stroke/TIA and 18% of patients had “incomplete 
evaluations”.   
We further investigated the counts per year of patients presenting with large artery 
atherosclerosis (Figure 1) and cardioembolic stroke/TIA (Figure 2) in each subgroup 
(“evident”, “probable”, “possible”).  We found a decrease in the counts of patients 
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having large artery atherosclerosis stroke/TIA (Figure 1) and an increase in the counts 
of patients presenting with a cardioembolic stroke/TIA (Figure 2).   
 
Figure 1. Graphical Illustration of the Counts of “Evident”, “Probable”, “Possible” and “Total” 
Large Artery Atherosclerosis Stroke/TIA.  
 
Figure 1 shows the same pattern of changing counts between “evident” and “total” causes of large 
artery atherosclerosis stroke or TIA. 
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Figure 2. Graphical Illustration of the Counts of “Evident”, “Probable”, “Possible” and “Total” 
Cardioembolic Stroke/TIA. 
 
Figure 2 shows the same pattern of changing counts between “evident” and “total” causes of 
cardioembolic stroke or TIA. 
 
In large artery atherosclerosis stroke/TIA, there was a significant decrease in 
“evident” causes from 116 cases in the year 2002 to 50 cases in the year 2012, in 
“probable” causes from 25 cases in the year 2002 to 9 cases in the year 2012 and in 
“possible” causes from 35 in the year 2002 to 15 in the year 2012.  Also, there was a 
significant increase in “evident” cardioembolic stroke/TIA from 29 patients in the 
year 2002 (40%) to 66 patients in the year 2012 (45%).  Similarly, there was a 
significant increase in “possible” cardioembolic stroke/TIA from 16 cases in the year 
2002 (22%) to 59 cases in the year 2012 (40%).   
In addition to the baseline characteristics of our population, we investigated the 
number of imaging tests patients received for the diagnosis of their stroke or TIA.  
The results showed that 3,387 patients had carotid duplex ultrasound (98% of the total 
population) and 3,361 patients had TPA measurements.  This difference arose because 
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26 patients with symptomatic carotid stenosis and large artery atherosclerosis stroke 
or TIA had angiography and urgent endarterectomy before they received a 
measurement of their TPA.  Also, 1,221 patients had transcranial Doppler ultrasound 
(35%).  In terms of cardiology investigations, 1,502 patients received an 
echocardiogram (44%), and 807 patients had a 24 hour or 48 hour Holter monitoring 
of their cardiac rhythm (23%).  Also, all patients had resting electrocardiograms at the 
time of their event in the emergency department.  In terms of brain imaging, 2,346 
patients had CT (68%), 1,320 patients had MRI (38%), 2,980 patients had either CT or 
MRI (87%), and 686 patients had both CT and MRI (20%).  Patients with 
cardioembolic stroke/TIA had significantly more diagnostic imaging tests compared 
to all other ischemic stroke subtypes (p<0.05).   
 
3.2 Secular Trends in Ischemic Stroke Subtypes 
Based on our primary objective, we wanted to assess whether there is any change in 
the secular trends in stroke/TIA subtypes in the Thames Valley area between the years 
2002 and 2012.   
 
Poisson regression analysis with spline trend function was used to test the hypothesis: 
Ho: There is no trend in the counts of stroke/TIA  
HA: A significant trend in the data exists 
 
The results of our analysis showed no significant trend in the counts of all 
strokes/TIAs and in men and women separately of the total cohort of patients with 
stroke/TIA (Figure 3).  The Delta (Δ) shown on the plots represent the percentage 
change from the trend line between the first clinic in 2002 and the last clinic in 2012.   
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Figure 3. Trend Analysis of All Patients with Stroke/TIA 
 
Figure 3 shows no change in the counts of all patients presenting between 2002-2012 (p>0.05).  
Similarly, no trend is shown in separate analyses of men and women (p>0.05). 
 
However, separate analyses for each stroke/TIA subtype show a significant increase in 
the counts of cardioembolic strokes/TIAs and a significant decrease in the counts of 
all other stroke/TIA subtypes (Figure 4).  The number and the percentage of each 
stroke/TIA subtype per year are presented in Table 7. 
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Figure 4. Poisson Regression with Fitted Spline Function of the Counts of Stroke/TIA Subtypes.   
 
Figure 4 shows a significant increase in cardioembolic stroke/TIA (CA) and a significant decrease in 
large artery atherosclerosis (LA), small vessel disease (SA), other rare or unusual cause (OC) and 
undetermined etiology of stroke/TIA (UC) (p<0.05). 
 
There is no evidence of serial correlation in the deviance residuals for the Poisson 
spline regressions for small vessel disease, other rare or unusual causes and 
undetermined causes of stroke/TIA, so the p-values are correct.  In the case of large 
artery atherosclerosis and cardioembolic stroke/TIA the serial correlation is slightly 
negative (large artery atherosclerosis p-value=0.016, cardioembolic p-value=0.0001).  
This means the test is conservative, that is, the true p-values are even slightly smaller 
in magnitude.  Indeed, the Mann-Kendall trend test with blocked bootstrap showed 
that the p-values for large artery atherosclerosis and cardioembolic stroke/TIA are 
more significant as compared to the Poisson regression with spline function.  The 
hypothesis tested using the Mann-Kendall test was the following: 
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Ho: There is a stationary time series 
HA: A monotonic trend with random autocorrelation errors exists 
To further determine the possible extent of the change in counts of presenting 
stroke/TIA subtypes, we investigated the change in the population covered by the 
Urgent TIA Clinic, based on information from Statistics Canada.  There was a 7.5% 
increase of the coverage population (Appendix C).  A repeat analysis, using as an 
outcome the rate in the change of number of patients presenting with stroke/TIA based 
on the change of the population (rate=count/population), showed the same results 
(Figure 5).  There was again a significant increase in the rate of cardioembolic 
stroke/TIA and a significant decrease in all other stroke/TIA subtypes.   
Figure 5. Poisson Regression with Fitted Spline Function Adjusting for the Change at the 
Population Level of Stroke/TIA Subtypes. 
 
Figure 5 shows a significant increase in cardioembolic stroke/TIA (CA) and a significant decrease in 
large artery atherosclerosis (LA), small vessel disease (SA), other rare or unusual cause (OC) and 
undetermined etiology of stroke/TIA (UC) (p<0.05). 
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The change in the population was highly correlated with the variable representing the 
number of clinic days when patients presented with stroke/TIA.  Since there was no 
change in the trends adjusting for the change at the population level, we removed the 
variable representing the change at the population level from our statistical model.   
Age did not have a role in the trends found in stroke/TIA subtypes.  We used the 
average age of patients presenting with stroke/TIA at the clinic on a given date as a 
response variable and we did not find sufficient evidence for any trend in stroke/TIA 
subtypes (Figure 6).  As a result, the significant trends that we observed earlier are not 
a result of a change in the patients’ age.   
 
Figure 6. Secular Trends of the Average Age of Stroke/TIA Patients in each Stroke/TIA Subtype. 
 
Figure 6 shows that there is no change in the average age of patients presenting with stroke/TIA on a 
given clinic day. 
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A further analysis that separated men from women shows the same trends in both 
sexes.  There was a significant increase in cardioembolic stroke/TIA in women from 
21% in the year 2002 to 62% in the year 2012 (Table 8).  Figure 7 shows that Poisson 
regression with a fitted spline function demonstrates the increase in cardioembolic 
stroke/TIA and the decrease in all other stroke/TIA subtypes (p<0.05) in women.  
Trends remained significant even after adjusting for population change (Figure 8).   
 
Figure 7. Poisson Regression with Fitted Spline Function in the Counts of Women with 
Stroke/TIA. 
 
Figure 7 shows a significant increase in cardioembolic stroke/TIA (CA) and a significant decrease in 
large artery atherosclerosis (LA), small vessel disease (SA), other rare or unusual cause (OC) and 
undetermined etiology of stroke/TIA (UC) (p<0.05) in women. 
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Figure 8. Poisson Regression with Fitted Spline Function Adjusting for the Change at the 
Population Level in Women with Stroke/TIA 
 
Figure 8 shows a significant increase in cardioembolic stroke/TIA (CA) and a significant decrease in 
large artery atherosclerosis (LA), small vessel disease (SA), other rare or unusual cause (OC) and 
undetermined etiology of stroke/TIA (UC) (p<0.05) in women. 
 
Similarly, there was a significant increase in cardioembolic stroke/TIA in men 
(p<0.05) from 21% in the year 2002 to 50% in the year 2012 (Table 9).  Poisson 
regression analysis (Figure 9) and adjustment for population change (Figure 10) show 
the same results.  
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Figure 9. Poisson Regression with Fitted Spline Function in Men with Stroke/TIA. 
 
Figure 9 shows a significant increase in cardioembolic stroke/TIA (CA) and a significant decrease in 
large artery atherosclerosis (LA), small vessel disease (SA), other rare or unusual cause (OC) and 
undetermined etiology of stroke/TIA (UC) (p<0.05) in men. 
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Figure 10. Poisson Regression with Fitted Spline Function, Adjusting for the Change at the 
Population Level in Men with Stroke/TIA. 
 
Figure 10 shows a significant increase in cardioembolic stroke/TIA (CA) and a significant decrease in 
large artery atherosclerosis (LA), small vessel disease (SA), other rare or unusual cause (OC) and 
undetermined etiology of stroke/TIA (UC) (p<0.05) in men. 
 
3.3 Baseline Population Characteristics and Stroke/TIA Risk Factors 
According to our secondary objective, we were interested in investigating the 
distribution of risk factors for stroke/TIA in all of our cases and separately in each 
stroke/TIA subtype. 
As expected, systolic blood pressure significantly decreased during the study period 
(p<0.05), reflecting the effectiveness of hypertension treatment in clinical practice 
(Figure 11).   
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Figure 11. Mean Blood Pressure of Patients with Minor Stroke/TIA Between 2002-2012. 
 
Figure 11 shows a significant decrease in systolic blood pressure and a significant increase in diastolic 
blood pressure (p<0.05) with no change in heart rate at the time patients presented with a first 
cerebrovascular event. 
 
Moreover, our patients exhibited a significant decrease in total cholesterol and LDL 
cholesterol, as well as demonstrating the increasing use of statins in treatment of 
hypercholesterolemia (Figure 12).  Also, there was a significant decrease in 
triglyceride levels (p<0.05).   
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Figure 12. Mean Total Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol of 
Patients with Minor Stroke/TIA Between 2002-2012. 
 
Figure 12 shows a significant decrease in total cholesterol, LDL cholesterol and triglyceride levels with 
a significant increase in HDL cholesterol (p<0.05). 
 
Our study demonstrates significant differences between men and women who had  
large artery atherosclerosis (41% vs. 25%, p<0.001), cardioembolic (34% vs. 41%, 
p<0.001), other rare or unusual causes (5% vs. 8%, p<0.001) and undetermined causes 
of stroke/TIA (11% vs. 15%, p<0.001), but there were no differences between men 
and women who suffered from small vessel disease stroke/TIA (10% vs. 10.4%, 
p=0.353) over the 10-year study period (Table 11).   
To further explore the risk factor characteristics of our population, we compared 
stroke risk factors in men and women.  The results showed that risk factors for 
stroke/TIA (smoking, BMI, systolic and diastolic blood pressure, total cholesterol, 
triglyceride, LDL, HDL, vitamin B12, homocysteine) are significantly different 
(p<0.05), except for age.  However, a closer investigation of each stroke/TIA subtype 
comparing risk factors in men and women revealed different results (Table 10).  
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Women with large artery atherosclerosis were not different from men in BMI, 
homocysteine, triglyceride or glucose levels.  Also, there were no significant 
differences between sexes with cardioembolic stroke/TIA in age, systolic blood 
pressure, vitamin B12, and triglycerides levels.  In patients with small vessel disease, 
no differences in BMI, total homocysteine, triglyceride and LDL cholesterol levels 
were observed between men and women.  Patients with other rare or unusual causes of 
stroke/TIA had no significant differences between two sexes in almost all risk factors 
(age, BMI, systolic blood pressure, total homocysteine, total cholesterol, triglyceride, 
LDL cholesterol, glucose).  Finally, no significant differences were found in age, BMI, 
systolic blood pressure, total homocysteine, LDL cholesterol or glucose levels in men 
and women with undetermined cause of stroke/TIA (p>0.05).   
We performed a stepwise logistic regression analysis to explore the role of risk factors 
in each stroke/TIA subtype.  Collinearity between predictors was assessed by 
measuring the correlation of each variable with all other predictors (Figure 13).  The 
results show high correlation between systolic and diastolic blood pressure; therefore, 
we included only systolic blood pressure in our regression model.   
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Figure 13.  Correlation Between Predictors to Assess Collinearity. 
 
 
Stepwise logistic regression shows that large artery atherosclerosis stroke/TIA is 
related to male sex, pack-years of smoking and systolic blood pressure in all age 
groups.  The further analysis that separated men from women demonstrates that 
presence of large artery atherosclerosis stroke/TIA was related to high pack-years in 
all age groups in both sexes.  Cardioembolic stroke/TIA was related with high levels 
of systolic blood pressure, pack-years and blood glucose in our cases.  In particular, 
men with cardioembolic stroke/TIA had high systolic blood pressure and increased 
pack-years as compared to women who had high levels of systolic blood pressure, 
pack-years and glucose.  Increased systolic blood pressure was the only risk factor 
related to small vessel disease in all patients of our cohort and separately in men and 
women.  Moreover, low levels of total homocysteine are related to stroke/TIA of other 
rare or unusual etiology in all patients and in women, whereas men with this subtype 
of stroke/TIA had high levels of LDL cholesterol.  In this subtype, any age over 60 
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years was related to having a stroke/TIA of other rare or unusual causes, something 
that was not shown in the separate analysis between men and women.  Finally, low 
levels of total homocysteine were related to undetermined cause of stroke in all 
patients and in men, and high levels of HDL cholesterol were related with strokes or 
TIAs of undetermined etiology in both sexes.   
 
Of note, the analysis of risk factors was conducted as an effort to describe the 
characteristics of our population, without providing evidence of a particular role of the 
aforementioned risk factors to the occurrence of each stroke/TIA subtype.   
 
3.4 Validation of SPARKLE 
Our tertiary objective was to assess the validity and the reliability of SPARKLE. 
A random sample of 25 cases per year from the initial 880 cases (25.5% of the cohort), 
was chosen to compare SPARKLE with CCS based on the best scenario of cases that 
fulfilled the ideal criteria of classification under CCS.  Cases were also classified 
based on the TOAST classification, which is the most widely used classification 
system in previous studies.  Cases were selected based on the availability of brain 
imaging examination (all cases had at least one brain imaging; 75% had CT, 68% had 
MRI, 43% had both CT and MRI), and any combination of diagnostic tests that 
evaluated both intracranial and extracranial vascular systems (52% had CTA or MRA 
or both, 72% had transcranial Doppler ultrasound, 99.6% had carotid Doppler 
ultrasound).  The final random sample consisted of 122 men (44%) and 153 women 
(56%).  Mean age ± SD 57 ± 16 (mean age ± SD of men 59 ± 15, mean age ± SD of 
women 55 ± 17, p=0.064).   
The comparison of the three classification systems indicated substantial agreement 
between SPARKLE and CCS (κ-value=0.75), but fair agreement between SPARKLE 
and TOAST (κ-value=0.38).   
There were 18 more cases classified as large artery atherosclerosis under SPARKLE 
compared to different subtype assignment in CCS.  There were 15 cases classified as 
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undetermined in CCS because of a lack of the TPA criterion, one case had been 
misclassified as cardioembolic due to the omission of ipsilateral symptomatic stenosis, 
and two patients, who had an echocardiogram showing cardiac wall akinesia and 
clinical presentation compatible to large artery atherosclerosis and high TPA, were 
classified as cardioembolic in CCS and as large artery atherosclerosis in SPARKLE 
based on the TPA criterion in addition to the medical history and the physical 
examination.  Also, 23 more cases had large artery atherosclerosis in SPARKLE 
compared to TOAST; 21 cases had multiple cases or high TPA without stenosis were 
classified as undetermined in TOAST, and two cases were classified as cardioembolic, 
in the absence of TPA criterion.  Results are illustrated in the Venn diagram in Figure 
14. 
 
Figure 14. Venn Diagram of the Number of Concordant Cases with Large Artery Atherosclerosis 
Stroke/TIA Between SPARKLE, CCS and TOAST.  
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Concerning cardioembolic stroke/TIA, there were differences between the three 
classification systems (Figure 15), even though cardioembolic stroke/TIA is the 
prominent ischemic stroke/TIA subtype in SPARKLE and CCS (58.2% vs. 49.8%, 
p<0.05).  To illustrate, 20 cases with medical history and clinical examination strongly 
suggesting cardiac sources of embolism with negative imaging confirmation or 
identification of low-risk cardiac source of embolism (e.g. aortic valve calcification, 
etc.) were classified as “possible” cardioembolic stroke/TIA under SPARKLE and as 
“undetermined causes” of stroke/TIA under CCS and TOAST.  Also, 87 cases with 
multiple etiologies of stroke and most “probable” cause cardioembolic stroke/TIA 
were classified as cardioembolic with SPARKLE and CCS and as undetermined cause 
of stroke with TOAST.  In addition, three cases with multiple territory infarcts and 
missed cardiac sources of embolism were classified as other rare or unusual causes of 
stroke/TIA in CCS and TOAST, and as cardioembolic stroke/TIA in SPARKLE 
(Figure 15, Figure 16).  One other case with diagnosis of multiple territory infarcts 
was classified as cardioembolic under SPARKLE and TOAST and misclassified under 
other rare or unusual causes of stroke/TIA, given a medical history suggesting 
dissection, but with normal MRA that was missed during the review of additional 
diagnostic investigations (Figure 15, Figure 16).  Finally, one case with atrial septal 
defect and presence of the Factor V Leiden was classified as cardioembolic under 
SPARKLE, as other rare or unusual cause under CCS, and as undetermined cause of 
stroke/TIA subtype under TOAST (Figure 16).  
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Figure 15. Venn Diagram of the Number of Concordant Cases with Cardioembolic Stroke/TIA 
Between SPARKLE, CCS and TOAST.  
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Figure 16. Venn Diagram of the Number of Concordant Cases with Other Rare or Unusual 
Causes of Stroke/TIA Between SPARKLE, CCS and TOAST.  
 
 
The three classification systems exhibited non-significant differences concerning 
small vessel disease stroke/TIA (Figure 17).  One case with high TPA and MRI 
showing an acute infarct of unspecified small size was classified as large artery 
atherosclerosis in SPARKLE and as small vessel disease in CCS and TOAST.  
Moreover, three cases with medical history and clinical presentation and imaging 
compatible with small vessel disease stroke/TIA were classified as such in SPARKLE 
and CCS, but fell under the undetermined cause of stroke/TIA category in TOAST 
with the presence of additional causes of stroke/TIA.  There was a significant 
difference in the undetermined cause of stroke/TIA subtype between the three 
classification systems (Figure 18).  There were 15 patients classified as large artery 
atherosclerosis and 20 cases classified as cardioembolic stroke in SPARKLE who fell 
under the undetermined category in CCS in the absence of TPA criterion and other 
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low risk of cardiac sources of embolism not included in the CCS criteria (p<0.05).  
Similarly, 131 cases with either multiple causes of embolism  (111 cases) or high TPA, 
without carotid stenosis, and otherwise large artery atherosclerosis stroke in 
SPARKLE were classified as undetermined causes of stroke/TIA in TOAST (p<0.05).   
 
Figure 17. Venn Diagram of the Number of Concordant Cases with Small Vessel Disease 
Stroke/TIA Between SPARKLE, CCS and TOAST.  
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Figure 18. Venn Diagram of the Number of Concordant Cases with Undetermined causes of 
Stroke/TIA Between SPARKLE, CCS and TOAST.  
 
 
Cardioembolic stroke/TIA was the predominant stroke/TIA subtype in SPARKLE and 
CCS, whereas undetermined cause of stroke/TIA was the predominant subtype in 
TOAST, as expected.  The comparison of the three classification systems shows a 
significant difference in large artery atherosclerosis, cardioembolic and undetermined 
cause of stroke/TIA (p<0.001), but no difference was found in small vessel disease 
and in other rare or unusual cause of stroke/TIA (Table 12).   
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3.5 Additional Analysis in the Validation Study 
We repeated the classification with the same 275 cases at one year after the 
stroke/TIA using SPARKLE, as well as for the follow-up events (recurrent stroke/TIA 
events at the follow-up period) using both SPARKLE and CCS.  The results showed 
an almost excellent agreement in SPARKLE between the baseline classifications and 
at the one year follow-up period (κ-value 0.95), and substantial agreement between 
first-ever stroke/TIA and recurrent events (κ-value 0.71).  Similarly, substantial 
agreement was shown between first-ever stroke/TIA and recurrent events based on 
CCS (κ-value 0.68).  
No significant differences in stroke/TIA subtypes were found in patients who had 
recurrent events as compared to those who had no such events (Table 13), except for 
cardioembolic stroke/TIA in SPARKLE.  From those patients having had a 
cardioembolic stroke/TIA, there were 133 cases with no recurrent events as compared 
to 27 cases who had a stroke/TIA at the follow-up period (p=0.038).   
In patients who had follow-up events, no significant difference was found between 
SPARKLE and CCS for all stroke/TIA subtypes (p<0.05), except for undetermined 
causes of stroke/TIA, where there was a significant difference in the categorization of 
the undetermined causes of first-ever stroke/TIA (p=0.02) as well as at the events 
during the follow-up period (p=0.01).  In particular, four cases in SPARKLE and nine 
cases in CCS were categorized as undetermined at the time of the first event and their 
cause of stroke/TIA remained undetermined during the follow-up period.  Also, 13 
cases in SPARKLE and 9 cases in CCS were categorized as large artery 
atherosclerosis at the first-ever stroke and at the recurrent stroke/TIA.  In addition, 26 
cases in SPARKLE and 22 cases in CCS were classified as cardioembolic at the time 
of their first and recurrent stroke/TIA.  In SPARKLE, there was only one case initially 
categorized as other rare or unusual cause of stroke/TIA that had an undetermined 
cause of stroke/TIA at the follow-up period of time.  However, three patients in CCS, 
who were initially classified as large artery atherosclerosis, small vessel disease and 
other rare or unusual causes of stroke/TIA, were classified as undetermined during the 
time of their recurrent stroke/TIA.   
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3.6 Reliability of SPARKLE 
We found an almost excellent intra-rater agreement (κ-value 0.91) and substantial 
inter-rater agreement (κ-value 0.76).  Moreover, the intra-class correlation coefficient 
was 0.94 for the intra-rater reliability and 0.81 for the inter-rater reliability.   
No significant differences in large artery atherosclerosis, cardioembolic and small 
vessel disease strokes between the raters (p<0.05) were identified, but there were 
significant differences in undetermined causes of stroke or TIA (p=0.003) and in other 
rare or unusual causes of stroke (p=0.031).  Firstly, six cases with cardioembolic 
stroke were classified as undetermined from one rater, and another eight cases with 
cardioembolic stroke were classified as undetermined by the other rater due to 
omission of clinical information suggesting cardiac sources of brain embolism with 
normal imaging investigations (e.g., multiple territory stroke or TIA with dyspnea or 
Valsalva maneuver at the onset of the event, prolonged sitting, etc.).  Secondly, one 
case with a stroke due to hypercoagulable state was classified as undetermined from 
one rater, and another five cases with rare or unusual causes of stroke or TIA (e.g., 
CADASIL, vertebral dissection, connective tissue disorders) were categorized as 
undetermined by the other rater due to omission of clinical and laboratory information.   
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Table 5. Baseline Characteristics of Patients Presenting with Stroke/TIA 
Age (mean±SD) 64.8±14.9 
Sex(males) [n(%)] 1693(50%) 
Body Mass Index>25 [n(%)] 2079(65%) 
Systolic Blood Pressure (mean±SD) 142±22 
Low-Density Lipoprotein (mean±SD) 3±1 
Glucose (mean±SD) 6±3 
Never Smoked n(%) 1318(38%) 
Active Smoker n(%) 682 (20%) 
Quit Smoking n(%) 1446 (42%) 
Antiplatelet medications used at baseline [n(%)] 1579(46%) 
Anticoagulant agents used at baseline n(%) 258 (8%) 
Medications used to treat hypertension [n(%)] 2137 (62%) 
Medications used to treat hyperlipidemia [n(%)] 1488(43%) 
Medications used to treat Diabetes Mellitus [n(%)] 470 (14%) 
Myocardial Infarction [n(%)] 418 (12%) 
Vascular Surgery [n(%)] 432 (13%) 
Atrial Fibrillation [n(%)] 307 (9%) 
Patent Foramen Ovale [n(%)] 489 (14%) 
Large Artery Atherosclerosis stroke/TIA subtype [n(%)] 1132(33%) 
Cardioembolic stroke/TIA subtype [n(%)] 1300(38%) 
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Small Vessel Disease stroke/TIA subtype [n(%)] 353 (10%) 
Other rare or unusual cause of stroke/TIA subtype [n(%)] 221 (6%) 
Undetermined cause of stroke/TIA subtype [n(%)] 439 (13%) 
Computed Tomography [n(%)] 2346(68%) 
Magnetic Resonance Imaging [n(%)] 1320(38%) 
Holter monitoring [n(%)] 807 (23%) 
Echocardiography [n(%)] 1502(44%) 
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Table 6. Patients with Cardioembolic Stroke/TIA and Atrial Fibrillation 
Anticoag+ INR≥2: Patients who succeeded on treatment with anticoagulant agents for atrial fibrillation and had INR≥2 
 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
AF 23 22 15 19 23 20 25 37 21 27 21 253 
Anticoag 
+ INR≥2 
2 4 2 4 8 3 5 12 4 4 3 51 
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Table 7. Distribution of Stroke/TIA Subtypes per year.  Percentages are presented in parentheses. n(%) 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
LAA 176(51) 158(46) 107 (39) 125 (37) 103 (33) 90 (28) 82 (24) 82 (22) 69 (30) 66 (26) 74 (28) 1132 (33) 
CAE 73 (21) 70 (20) 78 (28) 84 (25) 98 (31) 127 (39) 154 (46) 184 (50) 146 (53) 139 (54) 147 (56) 1300 (38) 
SVD 29 (8) 44 (13) 37 (14) 46 (14) 42 (13) 29 (9) 32 (10) 36 (10) 24 (9) 16 (6) 18 (7) 353 (10) 
Other 29 (8) 34 (10) 26 (10) 30 (9) 19 (6) 20 (6) 17(5) 13 (4) 10 (4) 11 (4) 12 (5) 221 (6) 
UND 41  (12) 39 (11) 27 (10) 53 (16) 51 (16) 60 (18) 52 (15) 52 (14) 28 (10) 26 (10) 10(4) 439 (13) 
Total 348 345 275 338 313 326 337 367 277 258 261 3445 
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Table 8. Distribution of Stroke/TIA Subtypes per year in Women.  Percentages are presented in parentheses. n(%) 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
LAA 78 (44) 58 (35) 48 (32) 45 (27) 37 (24) 38 (23) 26 (15) 29 (15) 26 (19) 29 (22) 28 (20) 442(25) 
CAE 37 (21) 32 (20) 47 (31) 49 (29) 56 (36) 67 (41) 95 (55) 111(57) 73 (55) 71 (55) 87 (62) 725(41) 
SVD 15 (9) 27 (17) 20 (13) 22 (13) 21 (14) 16 (10) 19 (11) 14 (7) 11 (8) 7 (5) 11 (8) 183(10) 
Other 17 (10) 22 (13) 17 (11) 24 (14) 10 (6) 14 (9) 6 (3) 12 (6) 7 (5) 6 (5) 6(4) 141 (8) 
UND 29 (17) 25 (15) 20 (13) 27 (16) 32 (21) 30 (18) 28 (16) 28 (14) 17 (13) 17 (13) 9(6) 262(15) 
Total 176 164 152 167 156 165 174 194 134 130 141 1753 
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Table 9. Distribution of Stroke/TIA Subtypes per year in Men.  Percentages are presented in parentheses. n(%) 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
LAA 98(57) 100(55) 59 (48) 80 (47) 66 (42) 52 (32) 56 (34) 53 (31) 43 (30) 37 (29) 46 (38) 690(41) 
CAE  36 (21) 38 (21) 31 (25) 35 (21) 42 (27) 60 (37) 59 (36) 73 (42) 73 (51) 68 (53) 60 (50) 575(34) 
SVD  14 (8) 17 (9) 17 (14) 24 (14) 21 (13) 13 (8) 13 (8) 22 (13) 13 (9) 9 (7) 7(6) 170(10) 
Other 12(7) 12 (7) 9 (3) 6 (4) 9 (6) 6 (4) 11 (7) 1 (1) 3(2) 5 (4) 6(5) 80 (5) 
UND  12(7) 14 (8) 7 (6) 26 (15) 19 (12) 30 (19) 24 (15) 24 (14) 11 (8) 9 (7) 1(1) 177(11) 
Total 172 181 123 171 157 161 163 173 143 128 120 1692 
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Table 10.  Comparison of Risk Factors for Stroke/TIA in Men and Women in all Stroke/TIA Subtypes. 
 LAA CAE SVD Other Etiology Unknown Cause 
 MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN 
Age 69±11 72±1 63±15 62±17 63±13 68±14 55±14 53±15 62±15 64±16 
p<0.001* p=0.134 p=0.001* p=0.278 p=0.439 
Pack 
Years 
27±27 18±23 17±21 8±15 18±23 11±18 19±25 6±10 16±20 10±15 
p<0.001* p<0.001* p=0.003* p<0.001* p<0.001* 
BMI 27±5 27±6 28±5 27±6 29±5 28±6 28±5 28±7 28±5 27±5 
p=0.549 p=0.016 p=0.049 p=0.872 p=0.060 
SBP 143±20 151±24 135±18 136±19 156±21 162±27 139±17 138±19 140±19 142±19 
p<0.001* p=0.211 p=0.011 p=0.532 p=0.294 
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Table 10.  Comparison of Risk Factors for Stroke/TIA in Men and Women in all Stroke/TIA Subtypes (continue from page 77). 
 LAA CAE SVD Other Etiology Unknown Cause 
 MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN 
DBP 80±12 78±14 81±11 78±12 91±14 88±15 86±13 81±13 83±11 79±11 
p=0.006 p<0.001* p=0.025 p=0.004 p<0.001* 
HR 68±12 71±12 70±13 71±12 72±13 73±13 74±13 74±13 70±12 72±11 
p<0.001* p=0.076 p=0.407 p=0.921 p=0.151 
Homo- 
cysteine 
13±15 12±6 12±7 11±10 11±5 11±5 11±4 8±4 10±3 10±5 
p=0.455 p=0.031 p=0.149 p<0.001* p=0.377 
Vitamin 
B12 
307±173 360±261 318±196 335±203 302±149 367±254 300±182 321±160 295±161 354±276 
p<0.001* p=0.132 p=0.006 p=0.382 p=0.014 
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Table 10.  Comparison of Risk Factors for Stroke/TIA in Men and Women in all Stroke/TIA Subtypes (continue from page 78). 
 LAA CAE SVD Other UND 
 MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN 
Total 
Chol. 
5±1 5±1 5±1 5±1 5±1 5±1 5±1 5±1 5±1 5±1 
p<0.001* p<0.001* p<0.001* p=0.292 p=0.002* 
Trigly- 
cerides 
2±1 2±1 2±1 2±1 2±2 2±1 2±2 2±1 2±2 2±1 
p=0.293 p=0.047 p=0.268 p=0.136 p=0.008 
HDL 1±0 1±0 1±0 2±0 1±0 2±0 1±0 2±0 1±0 2±1 
p<0.001* p<0.001* p<0.001* p<0.001* p<0.001* 
LDL 3±1 3±1 3±1 3±1 3±1 3±1 3±1 3±1 3±1 3±1 
p=0.001* p<0.001* p=0.072 p=0.869 p=0.216 
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Table 10.  Comparison of Risk Factors for Stroke/TIA in Men and Women in all Stroke/TIA Subtypes (continue from page 79). 
 LAA CAE SVD Other UND 
 MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN MEN WOMEN 
Glucose 7±4 6±2 6±4 6±2 7±3 7±2 6±1 6±2 6±2 6±2 
p=0.217 p=0.010 p=0.024 p=0.298 p=0.801 
*Using Bonferroni correction to control for multiple testing in the 13 tests applied in each stroke/TIA subtype and have significant test at the 
level of significance 5%, we calculate that p=0.05/13=0.004. 
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Table 11. Comparison of Stroke/TIA Subtypes in Men and Women. 
 MEN WOMEN p-value 
 n % n %  
LAA 690 41 442 25 <0.001 
CAE 575 34 725 41 <0.001 
SVD 170 10 183 10 0.35 
Other 80 5 141 8 <0.001 
UND 177 11 262 15 <0.001 
Total 1692 49 1753 51  
 
Table 12. Comparison of SPARKLE, CCS and TOAST  
 SPARKLE  CCS TOAST  SPARKLE vs 
CCS p-value 
SPARKLE vs 
TOAST p-value 
 n % n % n % 
LAA 59 22 40 15 36 13 7.629e-06 2.384e-07 
CAE 160 58 138 50 50 18 1.049e-05 <2.2e-16 
SVD 19 7 20 7 17 6 1 0.625 
Other 15 6 20 7 19 7 0.125 0.0625 
UND 22 8 57 21 153 56 5.821e-11 <2.2e-16 
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Table 13. Comparison of Patients Who Had Recurrent Stroke/TIA During the 
Follow-Up Period (FU Events) with Patients Who Remained Symptom-Free 
During the Follow-Up Period (NO FU). 
 SPARKLE CCS 
 NO FU FU Events p-
value 
NO FU FU Events p-
value 
 n % n % n % n % 
LAA 44 20 15 27 0.07 30 14 11 20 0.07 
CAE 133 61 27 49 0.04 114 52 24 44 0.07 
SVD 15 7 4 7 0.23 16 7 4 7 0.23 
Other 11 5 4 7 0.19 14 6 5 9 0.18 
UND 17 8 5 9 0.20 46 21 11 20 0.15 
Total 220  55   220  55   
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CHAPTER FOUR: DISCUSSION 
 
4.1 Summary of Findings in Stroke/TIA Subtypes and Risk Factors 
To our knowledge, this is the first retrospective case series study in a Canadian 
geographically defined area assessing secular trends in ischemic stroke subtypes in 
patients with minor stroke/TIA.  We performed a paper chart review of approximately 
3,950 cases and created a dataset of 3,445 newly diagnosed patients who experienced 
a first-ever stroke or TIA between the years 2002 and 2012 in the Thames Valley area 
in Ontario.  Our findings confirm a trend of increasing cardioembolic stroke/TIA 
subtype in patients with minor stroke/TIA and a decrease in all other stroke/TIA 
subtypes (p<0.05), which is in agreement with studies in other countries.
23, 24
   
Approximately 50% of all patients with AF and almost one third of patients with 
cardioembolic stroke/TIA and AF were treated for their arrhythmia, which is different 
than an earlier study by Gladstone et al. who showed that, in the years 2003-2007, 
40% of patients with AF were receiving treatment.
170
  One possible explanation of this 
difference is that hospitalized patients are expected to have a more severe stroke and 
be less adequately treated compared to patients with minor stroke/TIA.  This 
knowledge will assist primary care physicians in investigating and treating cardiac 
sources of brain embolism more intensively in patients with minor stroke/TIA to 
prevent additional major strokes that will need hospital care or even lead to death. 
With better management of baseline stroke risk factors,
171
 we would expect that the 
number of new patients with stroke would decrease over time.  However, we could not 
find any significant change in the counts of patients presenting with confirmed 
stroke/TIA (Figure 3).  We considered that part of the problem might be the increase 
in the population as “baby-boomers” are now reaching older age, which might explain 
the higher incidence of stroke.  Nonetheless, there is no significant change at the 
population level, and the 7.5% increase had no effect on the trends for stroke/TIA 
subtypes in all patients in our cohort, as well as in men and women separately.  Trends 
remained the same in both sexes in direction and significance, even after adjusting for 
population change.  We believe that there is a decrease in older patients who were 
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admitted to hospital or who died from a stroke as compared to a constant number of 
younger patients who experienced a minor stroke/TIA.  Indeed, a population-based 
study in Canada showed a 28.2% decrease in deaths and a 27.6% decrease in 
hospitalization due to stroke, but there was not any report of patients with minor 
stroke/TIA.
15
  Further research is required to investigate the reasons for the remaining 
constant number of new patients presenting with minor stroke/TIA to prevent an 
increase in cerebrovascular events in this group of patients.   
In our study, cardioembolic stroke/TIA was the predominant subtype after the year 
2007 in all patients and in men, as well as in women after the year 2005.  On the 
contrary, large artery atherosclerosis stroke/TIA was the most frequent subtype before 
2007 in all patients and in men, as well as in women before the year 2005, and 
decreased thereafter.  One explanation is that the Canadian Hypertension Education 
Program (CHEP) was put in place in 1999, and offers training for physicians on better 
management of hypertension, which also resulted in decreasing systolic blood 
pressure in our cohort.
172
  Moreover, large artery atherosclerosis stroke/TIA was 
expected to decrease given that statins are among the most widely prescribed 
medications for cholesterol control, and this was confirmed by a decrease in LDL 
cholesterol levels in our patients.
173
  Similar results were illustrated previously when 
Spence et al showed in 2000-2007 that stroke risk factors of patients who experience a 
minor stroke/TIA at the time of their first event are better controlled over time.
171
  
Similar results were also shown by Abbott et al in Australia, where better treatment of 
baseline risk factors was observed,
174
 which probably influenced the decrease in large 
artery atherosclerosis and small vessel disease and resulted in a proportional increase 
in cardioembolic strokes.
57, 155
  Additional evidence of decreasing prevalence of 
atherosclerosis has been shown in studies using autopsy reports of U.S.A. military 
service members.  In these studies, the prevalence of coronary atherosclerosis was 
77% in 1953 in the Korean War and decreased to 45% in 1975 during the Vietnam 
War.
175, 176
  More recently, autopsy results showed that the prevalence of coronary 
atherosclerosis further decreased to 8.5% in soldiers who died in Iraq.
177
   
We further investigated the potential causes for a significant increase in patients 
presenting with cardioembolic stroke/TIA.  There was no change in patients 
presenting with MI or AF.  Moreover, in recent years, more patients with AF were 
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treated with anticoagulant agents even though there are still cases where the level of 
dosage failed to mitigate the effects of emboli formation in the heart.  Considering that 
our cohort had patients of younger ages compared to inpatients, we expected to find 
no change in patients with cardioembolic stroke/TIA due to AF.
138
  Young patients are 
more likely to have low-risk cardiac sources of embolism
67
 compared to older patients 
who are more likely to have AF
68
 and the risk of developing AF increases with 
advancing age.
112-115
  However, this finding is prone to change in light of more 
evidence if, in the future, it is proven that longer monitoring of cardiac rhythm is 
required to capture an event of AF or paroxysmal AF, which may be missed with the 
current standard practice of 24 hour or 48 hour Holter monitoring.   
Furthermore, we investigated the number of diagnostic tests ordered through the total 
study period.  Between the years 2002 and 2012, we found a marginal decrease in CT 
(70% in 2002 vs. 65% in 2012, p=0.04), but no significant difference in MRI (33% in 
2002 vs. 35% in 2012, p=0.06), which denotes the almost constant availability of 
brain imaging in patients of our cohort during the past ten years.  Nonetheless, there 
was a significant increase in Holter monitoring (14% in the year 2002 vs. 47% in the 
year 2012, p<0.05) and echocardiograms (37% in the year 2002 vs. 61% in the year 
2012, p<0.05) ordered.  One explanation of this increase can be the increased 
suspicion of the high prevalence of cardioembolic stroke/TIA in patients with minor 
stroke/TIA.  However, all patients were assessed by the same stroke expert (Dr. 
Spence) with the same clinical criteria and without a priori assumptions of the most 
“probable” or “possible” stroke/TIA subtype.  Also, additional tests (e.g., Holter, 
echocardiogram, etc.) were ordered after the first clinical assessment and in presence 
of symptoms and signs suggesting cardiac sources of embolism (e.g., infarcts in 
multiple vascular territories in the brain).  Consequently, if a misclassification bias 
exists, this will be non-differential and minimal.   
Life expectancy is increasing
65
 and stroke risk increases in older individuals.
66
  With 
better management of baseline stroke risk factors,
171
 we would expect to see an 
increase in age of patients presenting with stroke in more recent years compared to 
earlier years.  Surprisingly, patients in the year 2012 were almost one year younger 
than patients in 2002 (p=0.035).  However, this decrease in age was not significant in 
each sex separately, even though women and men in the year 2012 were still one year 
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younger compared to patients presenting in the year 2002.  There was a significant 
difference in the age of patients in different stroke/TIA subtypes.  Older patients were 
more likely to have large artery atherosclerosis stroke and younger patients were more 
likely to have other rare or unusual causes followed by cardioembolic stroke/TIA 
(Table 10).  Continuous campaigns from the Heart and Stroke Foundation have 
potentially contributed to an increasing awareness of stroke symptoms in younger 
patients who reach health care services earlier in the presence of minor warning 
symptoms.  More patients are knowledgeable about the warning symptoms of stroke 
and manage to be further referred to stroke clinics for thorough investigation and 
treatment of their minor stroke/TIA with an ultimate goal of preventing a massive 
stroke that could lead to great disability or death.  However, we had no measure of 
stroke symptom awareness in our patients, which is a potential limitation of our study.  
Also, because of the retrospective nature of our study design, our investigation for 
cardiac sources of embolism was not as thorough or complete as it could have been.  
Further prospective research is required to reveal all possible causes and mechanisms 
of cardiac sources of embolism.   
We developed SPARKLE, which was based on the previously validated CCS 
classification system, for the classification of stroke/TIA subtypes.  A comparison 
with previous studies using CCS
156, 157, 178
 showed a predominance of cardioembolic 
as compared to other stroke/TIA subtypes (Appendix D) and fewer cases classified as 
undetermined cause of stroke/TIA, as would be expected compared to previous 
classification systems.
44, 57, 58
   
Ay et al
156
 and Michael et al
178
 used data from hospitalized patients and found higher 
frequency in cardioembolic strokes, which is in line with results from a meta-analysis 
by Schulz and Rothwell.
136
  In this meta-analysis, there were significant differences in 
all stroke/TIA subtypes between hospitalized patients with major disabilities from a 
massive stroke and non-hospitalized patients with minor stroke/TIA, with hospitalized 
patients having higher frequency of cardioembolic strokes mainly due to AF and non-
hospitalized patients having higher frequency of small vessel disease strokes.
49, 58
  
Therefore, the results of our study cannot be directly compared with studies using data 
from hospitalized patients only. 
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Palm et al used a modification of CCS and showed again that cardioembolic stroke 
was the predominant ischemic stroke subtype in more recent years.
157
  Previous 
population-based studies show inconsistent results.  In Asian countries, small vessel 
disease is the most frequent stroke/TIA subtype.
51, 104, 179-181
  While Kubo et al showed 
a decreasing frequency in small vessel disease stroke and an increasing frequency of 
large artery atherosclerosis and cardioembolic strokes, small vessel disease remained 
the most predominant ischemic stroke subtype in Asia.
51
  The same group identified a 
gene (PRKCH), specifically found in Asians, to be related to higher risk of developing 
small vessel disease.
182
  Similarly, in population-based studies in South America, 
small vessel disease is the most frequent ischemic stroke subtype and is probably 
related to lifestyle and management of risk factors.
153, 183
  On the other hand, in 
Australia, in the year 1986, 13.6% of patients suffered from a cardioembolic stroke 
and 32.6% had small vessel disease stroke,
155
 whereas, in the years 2002-2003, 29.4% 
had cardioembolic strokes and 11.2% had small vessel disease,
57
 showing the 
predominance of cardiac sources of brain embolism in more recent years.  Similar 
changes are shown in the U.S.A. and in European countries, but the distribution of 
stroke/TIA subtypes is highly affected by the distribution and management of risk 
factors and, consequently, it is not possible to extract a single summary statistic.  This 
denotes the importance of studying a geographically defined population with follow-
up studies investigating the change in the distribution of risk factors and the 
stroke/TIA subtypes over time.   
In our study, mean age was approximately the same as in previous studies.
30, 56, 153, 156, 
184
  However, other studies with hospitalized stroke patients show higher mean age, 
probably related to the increased clinical severity of stroke in older ages requiring 
hospital care.
178, 185
  Different studies show a lower mean age in stroke patients, which 
is related to a higher prevalence of stroke risk factors in younger ages in parts of the 
world, such as African, Arabian Gulf or Asian countries.
154, 186
  In Canada, patients 
more than 65 years old are more likely to have a major stroke and be hospitalized with 
a mean age of 71, which is at least five years older than our cohort.
138
  A national 
study by Tu et al showed that patients who were admitted to hospital with stroke had a 
mean age of 75 years.
15
  This denotes that younger patients are more likely to have a 
minor stroke/TIA, and as a result, they require more intensive treatment to prevent 
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additional strokes that can lead to hospital admission or death as these high-risk 
patients grow older.   
Significant differences exist between men and women in the distribution of risk 
factors and in stroke/TIA subtypes.  As expected, men had significantly more large 
artery atherosclerosis stroke/TIA compared to women who had significantly more 
cardioembolic stroke/TIA.  Also, men with large artery atherosclerosis had higher 
pack-years compared to women with large artery atherosclerosis.  Nonetheless, in 
both sexes, the trends in increasing cardioembolic stroke/TIA and decreasing counts in 
all other stroke/TIA subtypes were similarly significant.  This finding indicates that, in 
both sexes, atherosclerotic risk factors are better controlled and cardiac risk factors for 
stroke/TIA are increasing.   
Stroke risk factors other than age were significantly different in men and women.  On 
the one hand, men had higher levels of pack-years, total plaque area, BMI, triglyceride, 
homocysteine and glucose, which might explain the higher proportion of large artery 
atherosclerosis stroke/TIA.  On the other hand, women had higher blood pressure, 
LDL and HDL cholesterol and B12 measurements.  Unmeasured genetic factors and 
differences relating to sex hormones may have prevented women from having the 
excess atherosclerosis observed in men.  Moreover, the regression analysis showed 
that systolic blood pressure was significantly related with large artery atherosclerosis, 
small vessel disease and cardioembolic stroke/TIA subtypes, as shown in previous 
studies.
29, 31, 183, 187
  Small vessel disease was not associated with diabetes mellitus, 
similar to previous studies that used a risk factor-free classification system.
188-191
  
Nonetheless, the results of our regression analysis are inconclusive given the stepwise 
analysis and the inability to determine the level of significance needed for multiple 
hypothesis testing, as well as due to the absence of a control group of individuals 
without cerebrovascular disease.   
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4.2 Ischemic Stroke Classification System 
In clinical practice, we need a simple and informative classification system for 
grouping patients into separate categories without omitting complicated cases.
192
  An 
ideal and useful classification system should include the minimal diagnostic tests 
necessary to reach an accurate diagnosis, reflecting real clinical practice, and to 
accommodate the latest diagnostic tools available to be used in different clinical 
settings.
192
  SPARKLE is a classification system that incorporates all the elements of 
an easy and thorough classification system.  In SPARKLE, all clinically relevant 
information is considered (medical history, physical examination and basic laboratory 
investigation) to achieve the most “probable” diagnosis.  It is flexible enough to allow 
additional testing to confirm or reject the initial diagnostic plan in a systematic way by 
using specific rules to prevent physicians from performing individual diagnosis.  
Moreover, it is a risk factor-free classification system that allows investigation of the 
role of risk factors in the subtypes of ischemic stroke
135
 as a useful tool in 
epidemiological studies.   
SPARKLE is based on information from medical history and physical examination, 
and is useful to guide medical management of patients with stroke/TIA.  It uses basic 
diagnostic testing applied in clinical practice (for example, brain imaging, 
echocardiography, Holter monitoring, carotid and transcranial ultrasound, etc.).  It 
introduces a diagnostic tool for atherosclerosis (TPA), which is easy to measure with a 
regular ultrasound machine,
134
 without any specific software requirements.
193
  In their 
recently published population-based study, Palm et al used CCS for categorizing their 
ischemic stroke patients, adding a criterion for “probable atherosclerosis” in cases 
with carotid stenosis <50%, brain lesions >1.5 cm and no cardiac source of 
embolism.
157
  In SPARKLE, we used an actual measurable quantity of atherosclerosis 
based on classified stroke risk to distinguish high risk large artery atherosclerosis 
(TPA≥1.19cm2) from low risk (TPA<0.12cm2).129   
SPARKLE provides a more comprehensive view of each stroke/TIA subtype than 
CCS without omitting cases under the “undetermined” category if there are more than 
two “possible” causes of stroke, a criterion not included in CCS.  This approach might 
suppress the “undetermined” category of stroke/TIA subtypes and inflate all other 
determined causes of stroke/TIA.  However, it creates more homogenous groups of 
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patients sharing similar clinical characteristics and prognosis.  In our study, the 10-
year prognosis shows that 12.2% of patients had a recurrent stroke/TIA, with other 
rare or unusual causes of stroke/TIA having the highest recurrent rates, followed by 
strokes/TIAs of “undetermined” etiology (Appendix E).  The 10-year risk of 
stroke/TIA in our cohort was lower than seen in previous studies,
194, 195
 suggesting 
that cases were treated according to the most precise cause of stroke/TIA with 
SPARKLE and, consequently, more strokes/TIAs were prevented.  This evidence is 
supported by the different prognosis of patients with large artery atherosclerosis, as 
compared to patients with undetermined cause of stroke/TIA.  This is in contrast with 
the TOAST trial, where patients in these two subtypes of stroke had a common 
prognosis, suggesting misclassification of large artery atherosclerosis cases under the 
undetermined category.
127
 
Adams et al discuss in the TOAST trial that small vessel disease strokes share similar 
risk factors with large artery atherosclerosis strokes.
127
  Indeed, it is not easy to 
differentiate the nature of small subcortical infarcts in the brain and declare with 
certainty that they are not caused by small emboli of atherosclerotic lesions formed in 
large vessels that perfuse the area of infarct or from embolic particles of cardiac origin.  
A genetic analysis showed that in patients with stroke of “undetermined” etiology and 
small deep infarcts on brain imaging, 34% had a genetic profile similar to 
cardioembolic stroke, 13% had a genetic profile compatible with large artery 
atherosclerosis and 47% were predicted to have small vessel disease.
196
  However, 
based on the current knowledge, we decided to retain the description of the classical 
clinical lacunar syndromes referred to as small vessel disease as previously described.  
We acknowledge that in light of emerging evidence about the nature of small vessel 
disease, this subtype of stroke/TIA might change in the future, as all stroke 
classifications are dynamic systems with a tendency toward evolution with 
incorporation of new discoveries.   
In our study, 13% of all patients, 8% of patients included in the random sample of the 
275 cases and 24% of consecutive patients included in the pilot study had 
“undetermined” cause of stroke/TIA.  Even though special effort was made to classify 
all patients into defined stroke etiologies, there is still a high portion of patients who 
receive conventional treatment to modify all identifiable risk factors, without 
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elucidating a specific mechanism causing the presenting stroke/TIA event.  Genetic 
analysis in these patients might be able to show a genetic profile similar to a defined 
subtype of stroke/TIA; however, based on the current evidenced-based management, 
this genetic profile would not be able to alter the received treatment, in the case where 
a specific mechanism of disease is not possible to be identified and treated.   
 
Validity of SPARKLE 
An inherent limitation of all stroke classification systems is the absence of a 
comparison with a gold standard.  The ideal gold standard is still the pathology 
examination to accurately prove the cause of a stroke or TIA, something that is 
unrealistic and impossible to obtain from survivors of cerebrovascular disease, and 
this explains why we cannot assess the criterion validity of SPARKLE.
197
  Instead, Ay 
et al proposed the most accurate classification system to date (CCS), based on 
evidence from the annual threshold of 2% stroke risk, to differentiate an “evident” 
from a “possible” cause of stroke.128  However, the ideal application of CCS required 
a full set of diagnostic investigation, currently not available in all stroke cases in all 
clinical settings.  Based on evidence suggesting the use of TPA in the diagnosis of 
large artery atherosclerosis strokes, we developed SPARKLE as a more applicable 
diagnostic tool in clinical practice to include all dimensions in each subtype of 
stroke/TIA to ensure content validity.  The results of the comparison with CCS, as a 
surrogate of a gold standard, using ideal cases best classified under CCS, show 
substantial agreement between the two systems (κ-value=0.749) indicating construct 
validity, but the results from the pilot study show that in real practice, the agreement is 
fair (κ-value=0.382).  Therefore, we decided to classify our cohort based on 
SPARKLE criteria, which are more applicable to our clinical practice.  
There were no significant differences between SPARKLE and CCS and TOAST in 
assignment of cases in small vessel disease and other rare or unusual causes of 
stroke/TIA subtypes.  While SPARKLE did not provide a better description of these 
two subtypes, it introduced more information for the classification of cases as large 
artery atherosclerosis and cardioembolic stroke/TIA subtypes, which were not 
provided by previous classification systems.  Indeed, in SPARKLE, with the inclusion 
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of TPA criterion, there were 18 more cases of large artery atherosclerosis compared to 
CCS and 23 more cases compared to TOAST.  As expected, no cases with large artery 
atherosclerosis were assigned in CCS and TOAST that were not classified under 
SPARKLE, denoting the accuracy of the classification of patients with this subtype.  
Similarly, SPARKLE was able to classify 20 more cases with “possible” 
cardioembolic stroke/TIA, not described previously in CCS.  However, 8 cases were 
misclassified due to omission of information either from the medical history or the 
additional diagnostic investigations, something that highlights the importance of a 
comprehensive medical history in the final management of cases.  Based on Figure 2 
that illustrates the changing counts between all subgroups in cardioembolic stroke, we 
see that the pattern of increasing counts was similar between “evident” and “total” 
counts in cardioembolic stroke/TIA; therefore, we believe that the aforementioned 
differences in additional “possible” cardioembolic cases, assigned in SPARKLE that 
were not previously described in CCS, will not affect the overall increasing trend in 
cardioembolic stroke/TIA.  
 
Reliability of SPARKLE 
The inter-rater reliability of SPARKLE (κ-value=0.763) was not significantly 
different from CCS (κ-value=0.8).198  Nonetheless, the greatest disagreement between 
the raters occurred in cases when information from the medical history was 
overlooked.  Reliable assignment of cases in each stroke/TIA subtype requires a 
thorough investigation of the agreement between declared symptoms from the medical 
history to signs identified during the physical examination, in relation to additional 
laboratory investigations.  Consideration of laboratory investigations with less weight 
placed on the clinical examination can lead to erroneous classification of cases and 
missed opportunities for accurate diagnosis and treatment options.   
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Consistency of Classifying Ischemic Stroke/TIA using SPARKLE 
There was a great consistency in classification of cases with SPARKLE at the time of 
their first stroke/TIA and in one year after this first event (κ-value=0.947).  This 
shows that with the current knowledge about stroke syndromes and with the available 
diagnostic tests, SPARKLE can be used to accurately diagnose patients with particular 
stroke/TIA subtypes and guide appropriate treatment with good predictive validity.  
Recurrent stroke/TIA occur shortly after the first event; therefore, the consistency 
between baseline and one year follow-up in SPARKLE shows that clinical cases are 
classified accurately and few cases are missed with conditions not treated at the time 
of the first stroke (e.g., paroxysmal atrial fibrillation missed in Holter monitoring, etc.).  
Moreover, there was no significant difference in follow-up events between SPARKLE 
and CCS, other than CCS classifying more cases under the “undetermined” causes of 
stroke/TIA category.  This analysis may be underpowered with only 55 individuals 
from the initial sample having a stroke/TIA at the follow-up period of time, and is 
greatly affected by the fact that all cases were treated prospectively based on the 
SPARKLE categorization.  However, based on SPARKLE, more cases are classified 
into defined stroke/TIA subtypes, which offers the opportunity to patients to receive 
intensive treatment to reduce their risk of recurrent stroke/TIA.  Nonetheless, the 
results are not conclusive, and a randomized clinical trial would be more appropriate 
to show the success of treatment by classifying and treating cases based on CCS as 
compared to SPARKLE, to measure the type and the frequency of additional 
cerebrovascular events occurring during the follow-up period. 
 
4.3 Strengths 
A considerable strength of our study is the large number of patients we were able to 
collect and the availability of all clinically relevant information in paper charts to 
classify patients in each stroke/TIA subtype.  Despite the large size of this study, data 
entry and cleaning lasted approximately only seven months and the final dataset was 
quickly ready for analysis, which is the reason for choosing a retrospective study 
design.  Clinical charts of patients with minor stroke/TIA were located in one clinical 
setting, which facilitated the collection of our data.  
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A major problem in previous studies was the lack of carotid Doppler ultrasound in the 
investigation of stroke cases.
57, 183
  This was not an issue in our study, given that 
almost all patients had carotid ultrasound.  This helped differentiate large artery 
atherosclerosis from strokes/TIAs caused by dissection or other vascular diseases and 
avoid misclassification bias due to incomplete diagnostic assessment.  Moreover, the 
availability of services from a tertiary teaching hospital allowed additional diagnostic 
testing for cardiac evaluation or other imaging and laboratory technologies, which 
might not be available in rural areas.  This might have contributed to the lower rate of 
cases with “undetermined” cause of stroke/TIA, compared to previous studies.156, 178   
Furthermore, the majority of previous studies used TOAST for classifying ischemic 
stroke subtypes with an increased number of “undetermined” cases.  The use of CCS 
managed to considerably eliminate that restriction, without being able to completely 
differentiate large artery atherosclerosis from “undetermined” causes of stroke, a 
limitation mentioned in another study that used CCS.
157
  The introduction of 
SPARKLE resolved this problem and enriched our study with criteria to classify 
stroke/TIA subtypes, which can be used elsewhere and reflect real clinical practice.  
Moreover, SPARKLE, as CCS, was able to classify patients with more than one cause 
of stroke into the most “probable” or most “possible” stroke/TIA subtype.  This 
reduced the number of “undetermined” causes of stroke/TIA and is probably 
responsible for inconsistent results in studies in the U.S.A. and Europe, where 
different classification systems have been used over time.   
Another significant strength of classifying our cases based on SPARKLE is the lack of 
a priori assumptions concerning stroke risk factors in each stroke/TIA subtype.  A 
meta-analysis by Jackson et al showed that risk-factor free classification systems were 
not able to show a role of diabetes mellitus in the pathogenesis of small vessel disease 
stroke, which was the case in our study, even if our regression results were 
inconclusive.
135
  Consequently, SPARKLE can be used in prospective studies 
investigating in more depth the role of risk factors in the pathophysiology of small 
vessel disease strokes and other stroke/TIA subtypes.   
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Also, a considerable strength in our study is that all cases were examined by the same 
stroke expert, who collected all information, diagnosed and treated patients in the 
same manner throughout the study period.  Therefore, we believe that any information 
bias will be non-differential.   
 
4.4 Limitations 
Spectrum and selection bias is a significant limitation in our study.  We were able to 
capture a representative sample of patients experiencing a minor stroke/TIA, but our 
conclusions cannot be generalized to all patients who die or experience a major stroke.  
Moreover, it is likely to have missed patients with minor stroke/TIA who did not seek 
medical attention or have not been referred to the clinic.  However, a study by 
Webster et al showed that in Ontario, patients who are not seen in a secondary stroke 
prevention center are more likely to have atrial fibrillation, myocardial infarction, 
conestive heart failure, diabetes, dementia and history of stroke as compared to 
patients who are seen in these clinical settings and are more likely to have history of 
hyperlipidemia.
199
  As a result, the incidence of cardioembolic stroke/TIA might be 
higher in the total population.  Nonetheless, this study can only serve as a starting 
point to provide evidence of stroke/TIA subtypes and risk factors in patients with 
minor stroke/TIA and motivate additional population-based studies in the same 
geographic area including all patients who die or experience a major or minor 
stroke/TIA.   
The retrospective nature of our study was a significant restriction to obtaining more 
information to characterize thoroughly our population.  Information such as race and 
socioeconomic status was not available in clinical charts.  Future research can 
probably obtain this information by matching the postal codes of the residencies of 
patients to geographic census areas to speculate neighborhood average income 
quintiles.  Also, information about physical activity and diet was collected through 
non-validated questionnaires, which prevented us from obtaining valid measurements 
of these variables.  Moreover, environmental risk factors were not available to be 
collected, even if this is not a significant limitation, given that our population comes 
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from the same geographically defined area and all patients share the same 
environmental risk factors.   
Diagnostic tests ordered in the earliest years might have been missed if they were not 
entered in the clinical chart, something that we believe is highly unlikely, given that 
all clinical, imaging and laboratory information was collected in the same manner 
throughout the study. All cases were assessed with standardized clinical criteria 
without a priori assumption about the most “probable” stroke/TIA subtype, and the 
investigation and clinical decision-making were based on thorough information from 
the medical history and the physical examination.  Therefore, we believe that if there 
is any bias, this would be minimal.  On the contrary, the introduction of TPA in the 
definition of large artery atherosclerosis would have been expected to inflate this 
category and would have biased our classification towards large artery atherosclerosis.  
However, we actually saw a significant decrease in this subtype of stroke/TIA, 
suggesting that if such misclassification bias exists, it would be minimal. 
The lack of a control group to compare risk factors and stroke/TIA subtypes was an 
important limitation for obtaining information about the significance of risk factors in 
the occurrence of particular stroke/TIA subtypes.  In addition, the lack of 
differentiation between patients with minor stroke and patients with TIA restricted us 
from further investigating the change in risk factors before and after the 
cerebrovascular event.  Cholesterol
41, 200
 and blood pressure
201
 are transiently 
decreasing after a stroke event, and this is not observed in TIA.  Consequently, we 
cannot infer any conclusions about the role of risk factors in each stroke/TIA subtype.  
Moreover, the lack of a pathology examination restricted us from measuring 
accurately the sensitivity and the specificity of SPARKLE, compared to the gold-
standard.   
A physician (Dr. Bogiatzi) performed the data entry and categorization of patients into 
stroke/TIA subtypes based on SPARKLE criteria and on the final diagnosis of the 
stroke expert (Dr. Spence) who examined all patients.  This is in contrast to previous 
studies, where neurologists categorized the cases.  However, controversial cases that 
required a more expert clinical decision were assessed with the stroke expert to ensure 
the accuracy of data entry.  Ideally, prospective studies should use all clinical and 
laboratory criteria from different physicians trained to use the classification system to 
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examine patients with stroke/TIA and assign the most appropriate stroke/TIA subtype 
at the time of clinical evaluation of individual stroke/TIA cases.   
Finally, it has been acknowledged that specific genetic markers are related to specific 
stroke/TIA subtypes.
182
  Cardioembolic stroke/TIA can be differentiated from large 
artery atherosclerosis stroke/TIA based on screening 40 genes.
202
  Also, 41 genes have 
been identified as different between patients with small vessel disease compared to all 
other stroke/TIA subtypes.
203
  Therefore, this study is limited by the lack of genetic 
profiles in enrolled patients.  Nonetheless, a study by Jickling et al showed that in 
patients with unknown cause of stroke/TIA based on previous classification systems, 
58% had a genetic profile compatible with cardioembolic stroke and 18% of patients 
were predicted to have large artery atherosclerosis stroke, even if they had no 
significant differences in hypertension, diabetes, hyperlipidemia and smoking 
status.
196
  We believe that based on SPARKLE we were able to identify more stroke 
causes in patients that would otherwise remain undiagnosed, but a genetic profile is 
needed to confirm our findings. 
 
4.5 Implications 
Even if patients who die from a major stroke decrease over time,
15
 the number of 
patients presenting with minor stroke/TIA has remained approximately the same.  This 
information is important to motivate future research toward identifying prevailing 
medical risk factors for patients with minor stroke/TIA.  These can then be 
ameliorated to decrease the incidence and burden of stroke/TIA.   
In this study, we saw a significant increase in cardioembolic stroke/TIA in a high 
proportion of patients with low risk cardiac sources of embolism, at a relatively 
younger age than expected.  This evidence is important for health care services.  
Previous studies have shown that cardioembolic strokes have a high recurrence rate 
compared to other stroke subtypes.  Moreover, as life expectancy increases,
65
 these 
younger patients with an initial cardioembolic stroke/TIA are at high risk of surviving 
for a longer time with disabilities due to additional strokes that will require expensive 
rehabilitation services.  Consequently, additional studies are required to thoroughly 
investigate low and high risk cardiac sources of embolism that predominate in patients 
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with minor stroke/TIA and provide the opportunity for intensive prevention strategies 
to decrease incidence and recurrence in this stroke subpopulation.   
Additional research in our patients with cardioembolic stroke/TIA and AF showed 
that therapeutic goals are suboptimal.  From 23 patients with AF and cardioembolic 
stroke/TIA in the year 2002, only two were treated with anticoagulant agents.  
Similarly, among 21 patients with AF and cardioembolic stroke/TIA in the year 2012, 
only four were treated, from whom only three achieved INR≥2.  This evidence should 
alarm primary care practitioners who follow patients with AF closely and motivate 
them to implement more stringent control of their anticoagulation to prevent 
unnecessary cardioembolic strokes/TIAs. 
A final contribution of our study is the introduction of a classification system of 
ischemic strokes that reflects current clinical practice and can be used in all clinical 
settings.  Using SPARKLE, we saw that the prognosis of patients varies in different 
stroke/TIA subtypes, denoting the improved categorization of patients based on the 
most probable etiology of their stroke/TIA.  This system can be used in clinical 
practice and in further epidemiological studies.  However, confirmation of the 
reliability of SPARKLE is required.   
 
4.6 Perspectives – Future Considerations 
This study illustrates for the first time in a Canadian population that cardioembolic 
strokes/TIAs have been increasing in the past ten years in patients with minor 
stroke/TIA.  This finding can motivate the design of a prospective population-based 
study to include investigation of all possible cardiac sources and mechanisms of brain 
embolism.  Such a study should ideally include information on genetic markers and 
race to more accurately classify stroke/TIA subtypes and investigate differences in 
subtypes and risk factors in different racial groups.  In addition, enrollment of 
individuals with no cerebrovascular disease and of the same age and sex is needed to 
serve as a control group to compare with stroke/TIA patients and to provide evidence 
of the role of risk factors on each stroke/TIA subtype.   
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An important limitation in this study is the inability to differentiate patients with 
minor stroke from patients with TIA.  In the latest update of the American Heart and 
Stroke Association, TIA was defined as a cerebrovascular event in the presence of 
transient neurological symptoms with no evidence of permanent necrosis on brain 
imaging.
3
  Nonetheless, in our cohort, patients that satisfied this definition of TIA had 
signs in the clinical examination of brain ischemia not shown on brain imaging, 
indicating presence of a stroke.  Further studies are required to revisit the criteria for 
differentiating between stroke and TIA.  This has considerable value in assessing the 
role of risk factors in each stroke/TIA subtype.  Serum cholesterol decreases 
transiently after a stroke
41, 200
 , probably because of hemodilution,
204, 205
 and also 
systolic blood pressure decreases steeply in hospitalized patients with large artery 
atherosclerosis and small vessel disease stroke as opposed to other ischemic stroke 
subtypes.
201
  These changes in cholesterol and blood pressure are not observed in 
patients with TIA.  Therefore, further research is required to refine current definitions 
of stroke and TIA, both in anterior and posterior brain circulations.  
SPARKLE has been validated in one centre by researchers who developed the criteria 
for categorizing patients into five stroke/TIA subtypes.  Further validation is required 
in multiple centers to assess the reliability of this classification system with different 
raters, not involved in the development of this system.  In SPARKLE, we included 
TPA measurements in the definition of large artery atherosclerosis and also measured 
prognosis in different stroke/TIA subtypes.  However, a cluster randomized clinical 
trial would provide the best possible evidence on the performance of SPARKLE 
compared to CCS.  In this clinical trial, clinical settings could be randomized to 
clinical care without measurement of TPA versus clinical care with measurement of 
TPA and, consequently, patients in the two types of settings will be categorized based 
on CCS versus SPARKLE, respectively.   
This could also be accompanied by examination of the genetic profile of all patients to 
identify which classification system can better identify patients of a particular 
stroke/TIA subtype confirmed by genetic markers significantly related to each 
stroke/TIA subtype.  A clinical trial of this design would assess the prognostic value 
of each classification system.  If it is proven that SPARKLE with TPA measurements 
contributes to better categorization of patients with large artery atherosclerosis or that 
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SPARKLE helps reduce the rate of recurrent strokes or TIAs, then ultrasound 
assessment of all patients should incorporate TPA measurements to guide treatment 
success.  This has been shown to be clinically effective,
206
 but it has not yet been 
tested in a clinical trial.  
 
4.7 Conclusions 
With more intensive medical therapy, a significant decrease in atherosclerotic risk 
factors was observed, with a significant decreasing trend in strokes/TIAs caused by 
large artery atherosclerosis or small vessel disease.  However, there was a 
significantly increasing trend in cardioembolic stroke/TIA in patients presenting with 
minor stroke/TIA between 2002-2012 in the Thames Valley area in Ontario.  Patients 
in 2012 were by one year younger compared to patients in 2002.  Also, many patients 
with cardioembolic stroke/TIA and AF did not receive anticoagulant agents and the 
few of them who were on anticoagulant treatment did not achieve INR≥2.0.  Our 
findings suggest that more intensive investigation of high and low-risk cardiac sources 
of embolism is required, and greater use of anticoagulant agents may be warranted.  
Also, further studies are required to investigate in more depth the risk factors leading 
to a minor stroke/TIA.   
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Table 1.1 Stroke/TIA Subtypes in North America Using Classification Systems Other Than TOAST 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Gross et 
al
207
  
1980 U.S.A. 
(Alabama) 
White and 
Black 
135 Yes No 7% 31% 15% - 47% 
LaRue 
et al
42
  
1982-
1985 
U.S.A. 2141 Yes No 73% 19% 8% - - 
Foulkes 
et al
46
  
1983-
1986 
U.S.A. 1273 Yes Yes 9% 19% 27% - 45% 
Sacco et 
al
48
  
1983-
1986 
U.S.A.-ALL 394 Yes No 19% 14% 32% - 35% 
U.S.A.-
Whites 
135 30% 18% 24% - 27% 
U.S.A.-
Blacks 
177 14% 15% 29% - 43% 
U.S.A.-
Hispanic 
82 
 
13% 5% 52% - 35% 
Petty et 
al
208
  
1985-
1989 
U.S.A. 
(Minnesota) 
 - Mixed 
454 Yes Yes 16% 29% 16% 3% 36% 
Jones et 
al
209
 
1987-
2008 
U.S.A. 
(ARIC study) 
861 Yes Yes 56% 23% 21% - - 
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Table 1.1 Stroke/TIA Subtypes in North America Using Classification Systems Other Than TOAST (continue from page 92) 
Woo et 
al
210
  
1993 U.S.A. - 
Black 
245 Yes No 7% 23% 21% 7% 42% 
Schneid
er et al
43
  
1993-
1994 
U.S.A. – 
White and 
Black 
1956 Yes Yes 12% 20% 16% 3% 50% 
White et 
al
59
  
1993-
1997 
U.S.A. – 
White/Black/ 
Hispanics 
427 Yes Yes 15% 20% 20% 1% 45% 
 
 
Table 1.2 Stroke/TIA Subtypes in North America Using TOAST Classification System. 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
TOAST 
Trial
45
 
1990-
1997 
U.S.A. 1268 Yes No 18% 21% 24% 2% 34% 
Saposnik et 
al
53
  
1997-
1999 
Boston – 
Caucasian 
479 Yes No 21% 29% 23% 13% - 
Argentina 
- Natives 
361 9% 15% 29% 16% - 
Koch et al
47
  1998-
2002 
U.S.A. 
Miami 
126 Yes No 16% 17% 44% 3% 21% 
Uchino et 
al
55
  
2000-
2002 
U.S.A. 
Texas 
402 Yes Yes 14% 21% 19% 1% 44% 
Rodriguez 
et al
44
  
2005 U.S.A. 175 Yes No 23% 19% 21% 6% 31% 
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SOUTH AMERICA 
 
Table 2.1 Stroke/TIA Subtypes in South America Using Classification Systems Other Than TOAST 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Del Brutto 
et al
153
  
1992 Ecuador-
Hispanics 
313 Yes Yes 7% 14% 43% 6% 29% 
 
 
Table 2.2 Stroke/TIA Subtypes in South America Using TOAST Classification System 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Saposnik et 
al
53
  
1997-
1999 
Boston – 
Caucasian 
479 Yes No 21% 29% 23% 13% - 
Argentina 
- Natives 
361 9% 15% 29% 16% - 
Lavados et 
al
183
  
2000-
2002 
Chile - 
Mixed 
184 Yes Yes 4% 27% 31% - 38% 
Rojas et al
49
  2003-
2006 
Argentina 535 Yes No 10% 16% 41% 1% 32% 
Vallejos et 
al
211
 
2007-
2009 
Chile 380 Yes No 29% 24% 15% 12% 20% 
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EUROPE 
Table 3.1 Stroke/TIA Subtypes in Europe Using Classification Systems Other Than TOAST 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Carrera 
et al
23
  
1979-
2003 
Switzerlan
d 
(Lausanne) 
5298 Yes No 33% 25% 17% 9% 17% 
Eriksso
n et al
28
  
1986 Sweden 309 Yes No 62% 23% 15% - - 
Arboix 
et al
24
  
1986-
2004 
Spain 2028 Yes No 27% 28% 27% 5% 13% 
Moulin 
et al
32
  
1987-
1994 
France 
(Besancon) 
1996 Yes No 35% 31% 6% 6% 23% 
Aszalo´ 
s et al
25
  
1990-
1996 
Hungary 
(Budapest) 
500 Yes No 55% 12% 30% 4% - 
Semper
e et al
41
  
1992-
1994 
Spain 
(Segovia) 
235 Yes Yes 11% 26% 31% 6% 26% 
Modreg
o et al
31
  
1994 Spain 
(Teruel) 
1855 Yes Yes 39% 16% 35% - 11% 
2001 27% 24% 25% - 24% 
Markus 
et al
30
  
1998 UK 
(London) 
 -White 
361   14%  13%   
Elbaz et 
al
27
  
2000 France -  
Caucasian 
460 Yes No 23% 16% 21% 4% 36% 
Polychr
onopoul
os et al
33
  
2001 Greece 
(Patra) - 
Caucasian 
351 Yes No 37% 20% 27% - 16% 
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Table 3.1 Stroke/TIA Subtypes in Europe Using Classification Systems Other Than TOAST (continue from page 95) 
 
Díaz-
Guzmán 
et al
212
 
2006 Spain 1779 Yes Yes 35% 20% 18% 3% 24% 
 
Table 3.2 Stroke/TIA Subtypes in Europe Using TOAST Classification System 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Kolominsky-
Rabas et 
al
213
  
1994-
1998 
Germany 583 Yes No 13% 27% 23% 2% 35% 
Henrotin et 
al
214
  
1994-
2004 
France 1487 Yes Yes 33% 36% 27% - 5% 
Roquer et 
al
215
  
1995-
2002 
Spain 1339 Yes No 19% 21% 11% 2% 46% 
Poppert et 
al
38
  
1995-
2004 
Germany 653   16% 22% 23% 5% 35% 
Paciaroni et 
al
37
  
1998 Italy 1284 Yes No 21% 20% 37% 6% 16% 
Grau et al
184
  1998-
1998 
Germany 5017 Yes No 21% 26% 21% 4% 33% 
Vemmos et 
al
54
  
1998-
2001 
Greece - 
Caucasian 
278 Yes No 21% 31% 27% - 21% 
Sciolla et 
al
34
  
1999 Italy 443 Yes No 33% 17% 30% 3% 17% 
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Table 3.2 Stroke/TIA Subtypes in Europe Using TOAST Classification System (continue from page 96)  
Jood et al
36
  1999-
2003 
Sweden - 
Caucasian 
566 Yes  12% 16% 21% 9% 42% 
Hajat et 
al
187
  
1999-
2005 
UK - 
Mixed 
1181 Yes Yes 9% 28% 27% 3% 32% 
Nencini et 
al
216
  
2001-
2002 
Italy 93 Yes No 28% 33% 23% - 16% 
Jerrard-
Dunne et 
al
29
  
2002 UK 1000 Yes Yes 26% 12% 23% 9% 30% 
Schulz et 
al
40
  
2002-
2003 
UK 596 Yes Yes 15% 22% 22% 6% 36% 
Alzamora et 
al
35
  
2003 Spain - 
Caucasian 
196 Yes Yes 19% 27% 29% - 26% 
Bejot et al
26
  2005-
2006 
France 332 Yes Yes 36% 24% 27% 13% 
Sartori et 
al
39
  
2006 Italy 71 Yes No 21% 32% 34% - 13% 
Naess et 
al
185
  
2006-
2009 
Norway 1098 Yes No 11% 28% 15% 3% 41% 
Ihle-Hansen 
et al
58
  
2007-
2008 
Norway 210 Yes No 11% 31% 31% - 26% 
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AFRICA 
 
Table 4. Stroke/TIA Subtypes in Africa Using TOAST Classification System 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Hoffmann 
et al
217
  
1992-
1998 
South 
Africa - 
Mixed 
972 Yes  27% 13% 27% 23% 10% 
Sagui et 
al
152
  
2003-
2004 
Dakar 75 Yes No 1% 13% 20% - 65% 
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ARAB COUNTRIES 
 
 
Table 5.1 Stroke/TIA Subtypes in Arab Countries Using Classification Systems Other Than TOAST. 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Awada 
et al
218
  
1982-
1991 
Saudi 
Arabia 
756 Yes No 67% - 33% - - 
Rajeh et 
al
219
  
1982-
1992 
Saudi 
Arabia 
545 Yes No 48% 21% 22% 5% 4% 
 
 
 
Table 5.2 Stroke/TIA Subtypes in Arab Countries Using TOAST Classification System. 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Al-Shammri 
et al
220
  
1995-
1999 
Kuwait 62 Yes No 31% 10% 60% - - 
Deleu et 
al
186
  
2006-
2007 
Arabian 
Gulf 
760 Yes No 39% 14% 36% 7% 4% 
 
 
 129 
ASIA 
 
Table 6.1 Stroke/TIA Subtypes in Asia Using Classification Systems Other Than TOAST. 
 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Yokota 
et al
221
  
1978-
1997 
Japan 
(Osaka) 
1382 Yes No 21% 27% 40% 12%  
Turin et 
al
181
  
1988-
2004 
Japan - 
Asian 
1389 Yes Yes 21% 23% 54% - 2% 
Kitamu
ra et 
al
222
  
1992, 
1997, 
2002 
Japan 
(Yao) 
357 Yes No 26% 16% 54% - 5% 
Adachi 
et al
223
  
1994-
1997 
Japan 
(Tokyo) 
171 Yes No 31% 22% 43% - 4% 
Yip et 
al
224
 
1995 China 676 Yes No 17% 20% 29% 6% 29% 
Kimura 
et al
225
  
1999-
2000 
Japan 
 
16922 Yes No 33% 22% 39% - - 
Ghande
hari et 
al
226
  
2001-
2005 
Iran 
(Khorasan) 
1392 Yes No 54% 12% - 3% 20% 
Kate et 
al
154
  
2008-
2009 
India  118 
 
Yes Yes 31% 6% 30% 4% 28% 
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Table 6.2 Stroke/TIA Subtypes in Asia Using TOAST Classification System. 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Tanizaki et 
al
104
  
1961-
1993 
Japan 298 Yes Yes 20% 19% 56% - 4% 
Kubo et al
51
  1961-
1973 
Japan 383 
 
Yes Yes 21% 11% 64% - 4% 
1974-
1986 
383 
 
21% 23% 54% - 2% 
1988-
2000 
383 
 
27% 24% 49% - 0% 
Sumer et 
al
227
  
1996-
2000 
Turkey 266 Yes No 9% 33% 25% - 33% 
Hong et 
al
179
  
1999-
2000 
Korea 131 Yes Yes 30% 14% 34% 23% 
Tan N.C. et 
al
180
  
1999-
2001 
Singapore 
- Asian 
109 Yes Yes 28% 12% 44% 17% 
Liou et al
228
  2001-
2002 
Taiwan 587 Yes No 41% 10% 44% 6% 
Liu et al
229
  2002 China 619 Yes No 19% 26% 20% - 35% 
Jung et al
230
 2002-
2010 
Korea 36,191 Yes No 36% 17% 25% 2% 20% 
Sharma et 
al
56
  
2003-
2004 
Singapore 
-Asians 
481 Yes No 14% 8% 48% 3% 27% 
Lee et al
231
 2004-
2006 
Taiwan 533 Yes No 26% 18% 33% 1% 22% 
Wu et al
232
  2007-
2008 
Taiwan 1161 Yes No 15% 12% 39% 2% 33% 
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OCEANIA 
 
Table 7.1 Stroke/TIA Subtypes in Oceania Using Classification Systems Other Than TOAST. 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Ward et 
al
155
  
1986 Australia 
(Perth) 
154 Yes Yes 25% 14% 33% - 29% 
 
 
 
Table 7.2 Stroke/TIA Subtypes in Oceania Using TOAST Classification System. 
Author Year Country-
Ethnicity 
# of 
Cases 
Inpatients Outpatients LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Feigin et 
al
57
  
2002-
2003 
New 
Zealand - 
Mixed 
1032 Yes Yes 6% 29% 11% 3% 51% 
Leyden et 
al
233
 
2009-
2010 
Australia 
(Adelaide) 
238 Yes Yes 16% 42% 11% 6% 25% 
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Table 8. Stroke/TIA Subtypes Using CCS Classification System 
 
Author Year Country-
Ethnicity 
# of 
Cases 
In-
patients 
Out-
patients 
LAA CAE SVD Other 
Cause 
Unknown 
Etiology 
Ay et al
156
  2000-
2006 
U.S.A. 
(Massachusetts) 
61 Yes No 30% 46% 0% 10% 15% 
Michel et 
al
178
  
2003-
2008 
Switzerland 
(Lausanne) 
1742 Yes No 27% 32% 15% 9% 17% 
Palm et 
al
157
  
2006-
2007 
Germany 626 Yes Yes 29% 35% 26% 1% 9% 
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APPENDIX B: Pilot Study Results 
 SPARKLE Large Artery 
Atherosclerosis 
CCS Large Artery 
Atherosclerosis 
 n % n % 
Evident 58 14.5 1 0.3 
Probable 9 2.3 0 0 
Possible 8 2 33 8.3 
 SPARKLE Cardioembolic CCS Cardioembolic 
 n % n % 
Evident 100  25% 0 0 
Probable 17  4.3% 0 0 
Possible 66  16.5% 45 11.3 
 SPARKLE Small Vessel Disease CCS Small Vessel Disease 
 n % n % 
Evident 9  2.3% 0 0 
Probable 8  2% 0 0 
Possible 20  5% 13 3.3 
 SPARKLE Other rare or 
unusual causes 
CCS Other rare or unusual 
causes 
 n % n % 
Evident 3  0.8 0 0 
Probable 2 0.5 0 0 
Possible 5 1.3 3 0.8 
 SPARKLE Undetermined 
Causes 
CCS Undetermined Causes 
 n % n % 
Cryptogenic -  7 1.8 
Incomplete 
Evaluation 
70 17.5 272 68 
Unclassified 25 6.3 26 6.5 
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APPENDIX C: Thames Valley Area Population
234, 235
 
  2001 2006 2011 
Oxford 
Country: 
Blansford-Blenheim 7422 7149 7359 
East Zorra-Tavistock 7238 7350 6836 
South-west Oxford 7782 7589 7544 
Ingersoll 10977 11760 12146 
Tillsonburg 14052 14822 15301 
Woodstock 33269 35480 37754 
Zorra 8052 8125 8058 
Elgin 
Country: 
Aylmer 7158 7069 7151 
Bayham 6375 6727 6989 
Central Elgin 12293 12723 12743 
Dutton/Dunwich 3696 3821 3876 
Malahide 8777 8828 9146 
Southwold 4487 4724 4494 
St. Thomas 33303 36110 37905 
West Elgin 5464 5349 5157 
Middlesex 
Country: 
Strathroy-Caradoc 19154 19977 20978 
Southwest Middlesex 6144 5890 5860 
Adelaide-Metcalfe 3109 3135 3028 
Lucan-Biddulph 4201 4187 4338 
Middlesex Centre 14242 15589 16487 
North Middlesex 6901 6740 6658 
Thames Centre 12473 13085 13000 
City of London  
336539 352395 
Muncee-Delaware Nation  
0 167 
Chippewa of the Thames First Nation  
0 747 
Total 573108 599538 619881 
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APPENDIX D. Comparison of Stroke/TIA Subtypes with Studies Using CCS. 
*LAA=Large-Artery Atherosclerosis, CAE=CArdioEmbolic, SVD=Small Vessel Disease, Other=Other 
rare or unusual causes, UND=Undetermined causes of stroke/TIA 
 
 Country Year # of 
cases 
LAA
*
 CAE
*
 SVD
*
 Other
*
 UND
*
 
Ay et 
al.
156
 
U.S.A. 2000 
2006 
61 30% 46% 0% 10% 15% 
Michael 
et al.
178
 
Switzerland 2003 
2008 
1742 27% 32% 15% 9% 17% 
Palm et 
al.
157
 
Germany 2006 
2007 
626 29% 35% 26% 1% 9% 
Bogiatzi 
et al. 
Canada 2002 
2012 
3445 33% 38% 10% 6% 13% 
 136 
APPENDIX E. 10-year Prognosis of Patients With Minor Stroke/TIA 
 Stroke/TIA All patients 
 n % N 
LAA
*
 127 11.2 1132 
CAE
*
 153 11.8 1298 
SVD
*
 38 10.7 354 
Other
*
 46 20.8 221 
UND
*
 56 12.7 440 
Total 420 12.2 3445 
*LAA=Large-Artery Atherosclerosis, CAE=CArdioEmbolic, SVD=Small Vessel Disease, Other=Other 
rare or unusual causes, UND=Undetermined causes of stroke/TIA 
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